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Background: Women who inherit a BRCA pathogenic variant are 6 times more likely to develop 
breast cancer and 4 times more likely to develop ovarian cancer over the course of their lifetime.  
These are devastating statistics for women who are told this, as carrying this mutation can have a 
significant impact on family planning decisions in these women who are of reproductive age.  
Since the primary preventative measures include risk-reducing surgery that can render women 
infertile, the psychological and physiological consequences can be overwhelming since cancer risk 
reduction must be balanced with family planning.  The aim of this study was to explore the role of 
emotional states on reproductive decision-making in women with a known BRCA pathogenic 
variant.     
Methods:  This exploratory, descriptive study included women with a BRCA pathogenic variant 
recruited from a familial cancer registry.  Data were collected via a validated questionnaire to 
measure emotional states, familial cancer registry records and medical records.  Logistic regression 
was performed to assess the relationship between emotional states, BRCA pathogenic variant status 
and individual factors on reproductive decision-making.  Descriptive statistics were used to 
characterize the sample of women.   
Results:  85 women completed data collection.  There were no significant interactions between 
emotional states and reproductive decision-making.  Age at genetic testing and number of children 
were significant for predicting being finished having children.  Women who had a female relative 
with ovarian cancer reported higher loss/benefit scores.   
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Conclusions:  Women who are older, and already have children are more likely to be finished 
having children.  Having a relative with ovarian cancer is associated with higher scores of 
loss/benefit when assessing probability of being finished having children.  Future research should 
identify women newly tested and follow them longitudinally to understand how emotional states 
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1.0 Proposal and Introduction 
Women who live in the United States have a 12% risk of developing breast cancer and a 
2% risk of developing ovarian cancer during their lifetime.  For women who carry a pathogenic 
BRCA1 or BRCA2 variant, one that affects approximately one in 200-400 women living in the 
United States, this risk increases (Kuchenbaecker et al., 2017a; Manickam et al., 2018).  For breast 
cancer, lifetime risk ranges from 55-70% for BRCA1 carriers by the age of 70 and between 45-
70% in BRCA2 carriers.  For lifetime risk of ovarian cancer, the risk ranges from 40-45% for 
BRCA1 and 15-20% for BRCA2 (Kotsopoulos, 2018; Kuchenbaecker et al., 2017a).  In addition to 
the increased personal risk, women with a BRCA pathogenic variant have a 50% chance of passing 
the pathogenic variant to their offspring (U. S. Preventive Services Task Force, 2019). 
Overall survival for BRCA associated breast and ovarian cancer is similar than that of 
women with breast or ovarian cancer who do not carry a BRCA pathogenic variant (Lieberman et 
al., 2019). However, due to the increased risk of cancer in these individuals, primary risk reduction 
strategies are often recommended, especially in those at increased risk for ovarian cancer.  Risk-
reducing surgical options may include bilateral mastectomy and bilateral salpingo-oopherectomy 
(U. S. Preventive Services Task Force, 2019).   For a young woman who is not ready to make 
family planning decisions, these surgical procedures can be significantly life altering, especially 
in bilateral salpingo-oophorectomy, which renders a woman infertile (U. S. Preventive Services 
Task Force, 2019). 
Much research has focused on the myriad of issues associated with women who have tested 
positively for a BRCA pathogenic variant.  In the past ten years, requests for pathogenic variant 




identified factors influencing the decision to have BRCA testing including age, and the number of 
living children. (Battistuzzi et al., 2019; Claes et al., 2004; Halbert et al., 2011; Hesse-Biber et al., 
2016; Lynch et al., 2006; Nelson et al., 2005; Pasacreta, 2003).  Women with a BRCA pathogenic 
variant who have been diagnosed with cancer have experienced an increase in symptoms of 
distress, anxiety and depression in the first few months after genetic test disclosure (Beran et al., 
2008; Bosch et al., 2012; Claes et al., 2004; Graves et al., 2012; Halbert et al., 2011; Schwartz et 
al., 2002; Smith et al., 2008; van Dijk et al., 2006).  Other research has focused on the decision to 
have risk-reducing surgery. These studies also found this decision to be influenced by age, in 
addition to the desire for children, gender of living children and a family history of cancer 
(Battistuzzi et al., 2019; Gavaruzzi et al., 2017; Hesse-Biber, & An, 2016).   
Although women want to be logical in their decision-making, emotions may complicate 
this process.  By definition, emotions are complex, multi-dimensional judgments that reflect a 
great deal of information about one’s relationship to social and physical surroundings.  One’s own 
internal thoughts regarding these relationships are also reflected (Lambie & Marcel, 2002; Smith 
& Ellsworth, 1985).  Strong evidence supports the association of emotions and the decision to be 
tested for a BRCA pathogenic variant (Dean et al., 2017a; Rini et al., 2009; Werner-Lin, 2008).  
However, the role that emotions play in the reproductive decision-making process of women with 
a BRCA pathogenic variant is unknown.  Qualitative studies have examined the complex decisions 
influencing finding a partner and the timing of having children (Dean, 2016; Dean, & Rauscher, 
2017a; Dean et al., 2017b; Donnelly et al., 2013b; Rauscher et al., 2017).  However, no studies 
were identified that focused on the emotional aspect of reproductive decision-making. 
Lazarus and Folkman’s Transactional Model of Stress provides the foundation to better 




al., 2005; Lerner et al., 2001; Lerner et al., 2014; Lerner et al., 1999).  This model includes three 
basic dimensions, or emotional states; threat, challenge, and loss/benefit (Folkman et al., 1985).  
These emotional states are accompanied by core appraisal themes, which influence the likelihood 
of specific courses of action (Frijda, 2002; Lazarus, 1991; LeBlond, 2008).  Threat is referred to 
as the anticipation of psychological or physical damage or loss; challenge results from demands 
that a person feels confident about mastering and loss/benefit refers to psychological loss or gain 
that has yet to occur.  
The Agency for Healthcare Research and Quality (AHRQ) has been authorized by the U.S. 
Congress to convene the United States Preventive Services Task Force (USPSTF) and to provide 
ongoing scientific, administrative, and dissemination support to the Task Force.  The Task Force 
works to improve the health of all Americans by making evidence-based recommendations about 
clinical preventive services such as screenings, counseling services, and preventive medications 
(U. S. Preventive Services Task Force, 2019).  In their Final Evidence Synthesis for BRCA Related 
Cancer in Women, the Task Force reports that younger women are subjected to additional harms 
related to the impact of risk-reducing surgery on reproductive life decisions (U. S. Preventive 
Services Task Force, 2019).  These harms include an increase in anxiety, depression, distress and 
uncertainty.  It is safe to conclude that these harms can lead to various emotional states in women 
who are already distressed.  This study will focus on how the three emotional states of threat, 
challenge, and loss/benefit are associated with patient decision-making and eventual clinical 
outcomes, such as the decision to undergo risk-reducing surgery.   
The purpose of this study is to explore the role of emotional states on reproductive decision-





Specific Aim 1: Describe the distribution of a BRCA pathogenic variant among 
women who are in the Cancer Family Registry (CFR).  
The sample of women in the CFR will be described, including the distribution of BRCA1 
and BRCA2 pathogenic variants.  
Specific Aim 2: Explore the association between emotional states and reproductive 
decision-making. 
The primary emotional states of threat, challenge and loss/benefit, as defined by the 
Transactional Model of Stress, will be assessed using the Appraisal of Life Events scale 
questionnaire in women who are BRCA positive and have made or are making reproductive 
decisions.   
Specific Aim 3: Explore the association between individual factors (age, race, 
ethnicity, marital status, number of children and family history of breast and ovarian cancer) 
and reproductive decision-making.    
Individual factors (age at diagnosis, race, ethnicity, marital status, number of children and 
family history of breast and ovarian cancer) will be assessed to explore their influence on 
reproductive decision-making.  Individual factors will be assessed using a combination of self-
report and information from the medical record.     
Specific Aim 4: Explore how BRCA pathogenic variant status (BRCA1 vs BRCA2) 
moderates the relationship between emotional states and reproductive decision-making.  
BRCA pathogenic variant status, measured from the CFR, will be assessed to explore its 




Specific Aim 5: Explore how individual factors moderate the relationship between 
emotional states and reproductive decision-making.    
Individual factors will be assessed to explore their moderation between emotional states 
and reproductive decision-making.   
The results of this pilot study will provide critical information regarding emotions and 
reproductive decision-making to inform further research which may lead to successful 
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race/ethnicity, marital status, 
number of children, family 








1.2 Background and Significance 
1.2.1 Epidemiology of BRCA1 and BRCA2 Pathogenic variants 
Breast cancer genes BRCA1 and BRCA2 are genes that produce tumor suppressor proteins. 
The role of these proteins is to repair damaged DNA, thus ensuring the stability and integrity of 
each cell’s genetic material (National Cancer Institute, 2018a). When either of those genes are 
mutated, the repair work of damaged DNA may not occur. Because of the inability to repair DNA, 
additional genetic alterations occur, which can lead to cancer. Specific inherited BRCA pathogenic 
variants increase the risk for ovarian and breast cancers. Women who have inherited pathogenic 
variants in BRCA1 and BRCA2 tend to develop breast and ovarian cancers at younger ages than 
people who do not have these pathogenic variants. These gene pathogenic variants are responsible 
for 5% to 10% of all breast cancers and 10% to 15% of all ovarian cancers (Heald et al., 2016).  
The BRCA1 gene, discovered in 1994, is located on chromosome 17.  More than 1,200 variants 
have been associated with increased risks of cancer  (Nelson et al., 2019b). The BRCA2 gene, 
discovered in 1995, is located on chromosome 13.  More than 1,330 variants have been associated 
with increased risks of cancer (Nelson et al., 2019b).  
1.2.2 BRCA Pathogenic variant in the General Population 
Women who have a BRCA gene pathogenic variant have an increased risk of breast and 
ovarian cancer.  The estimates of risk are high: the chance of developing breast cancer by the age 
of 70 is 55-70% for BRCA1 carriers and 45-70% for BRCA2 carriers (Antoniou et al., 2008; Chen 




breast cancer diagnosis by the age of 70 (SEER, 2019).  To put these risk estimates into 
perspective, by the age of 70, in a group of 100 women without a BRCA1 or BRCA2 pathogenic 
variant, 7 will be diagnosed with breast cancer and in a group of 100 women with a BRCA 1 or 
BRCA2 pathogenic variant, 45-65 will be diagnosed with breast cancer.  For ovarian cancer, the 
difference in risk predictions are even higher.  The lifetime risk of ovarian cancer by the age of 70 
for women in the general population is less than 2% (American Cancer Society, 2018).  However, 
for women with a BRCA1 pathogenic variant, the risk increases to 40-45%.  Similarly, for women 
with a BRCA2 pathogenic variant, the risk increases to 10-30% (Genetics of Breast and 
Gynecologic Cancers, 2018).   
1.2.3 BRCA Pathogenic variant in High Risk Populations 
Specific BRCA pathogenic variants are clustered among certain groups, including 
Ashkenazi Jews, specific populations of Blacks and Hispanics, and in families in the Netherlands, 
Iceland and Sweden (Rafnar et al., 2004; Tryggvadottir et al., 2003; Vallee et al., 2012; Weitzel et 
al., 2003). Ashkenazi Jews have the highest prevalence of BRCA pathogenic variants among all 
the high-risk groups.  In this population, one in 40 women will have a BRCA pathogenic variant.  
Of the Ashkenazi Jewish women in the United States who have been diagnosed with breast cancer, 
10% of diagnoses are due to a BRCA pathogenic variant (King et al., 2003).  Approximately 5-
10% of women with breast cancer have a mother or sister with breast cancer and 20% have either 




1.2.4 Inheritance of a BRCA Pathogenic Variant 
Individuals can be assessed for their individual likelihood to carry a BRCA pathogenic 
variant based on their own personal and family histories of cancer.  BRCA pathogenic variants are 
inherited in an autosomal-dominant pattern, meaning that if one parent has the pathogenic variant, 
each offspring has a 50% chance of inheriting it (National Institute of Health, 2019).  Typically, 
most individuals discover that they are carriers when another family member, typically a mother, 
grandmother, aunt or sister, is diagnosed with either breast or ovarian cancer.  When an individual 
is found to carry a variant in one of the BRCA genes, there are a variety of surveillance, 
chemoprevention, and risk reducing surgical strategies available for consideration.  
1.2.5 Risk Management Strategies 
Clinical decision-making regarding which strategy to pursue for cancer risk reduction 
involves a consideration of life expectancy and quality of life.  Past research has suggested that 
decision aids or data from models may help individuals choose among various options (Grann et 
al., 2010; Kurian et al., 2009; Schrag et al., 1997, 2000; van Dijk et al., 2008).  Most of these 
options include using decision analysis and the concept of time tradeoffs, identifying the years of 
life saved by one strategy versus another.  Though these methods are used in a clinical research, 
they often are not used in clinical practice.  Clinical practice options include surveillance, 





Women with a BRCA pathogenic variant are encouraged to begin breast self-awareness at 
the age of 18, schedule clinical breast exams every 6 to 12 months beginning at age 25, and 
depending on the breast cancer history within the family, undergo annual breast MRI’s (magnetic 
resonance imaging) starting at the age of 25 (Committee on Practice Bulletins- Gynecology, 2017).  
Annual mammograms and MRI’s are recommended after the age of 30 years, preferably one or 
the other every 6 months.  For comparison, women without an increased risk to develop breast 
cancer begin mammograms at the age of 40 or ten years prior to the earliest diagnosis of breast 
cancer in their family.  There is no effective screening method to detect ovarian cancer (Committee 
on Practice Bulletins- Gynecology, 2017).  Surveillance is especially critical for women with 
BRCA1 and BRCA2 pathogenic variants because of their increased risk.   
1.2.5.2 Chemoprevention 
Chemoprevention has been evaluated as an option for high risk women.  It is defined as 
the inhibition of carcinogenesis using natural or synthetic agents (Murthy et al., 2019).  In both 
pre- and postmenopausal women, tamoxifen can be used for risk reduction, which may reduce 
breast cancer risk by 62% in BRCA2 pathogenic variant carriers (Goss et al., 2011; Nazarali et al., 
2014; Nelson et al., 2019a).  Oral contraceptives have been found to decrease ovarian cancer risk 
due to the inhibitory effect on ovulation, although contraceptives increase the risk for breast cancer.  
A case control study (n=799) found that oral contraceptives caused a reduced risk of ovarian cancer 
in carriers of BRCA1 pathogenic variants (odds ratio 0.56) and carriers of BRCA2 pathogenic 
variants (odds ratio 0.39) (McLaughlin et al., 2007).  In fact, individuals who use oral 
contraceptives for 5-10 years decrease their risk by 30-50% (National Cancer Institute, 2018b).  
Women with a BRCA pathogenic variant seek for cancer risk reduction while maintaining fertility.   
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1.2.5.3 Risk-Reducing Surgery 
Risk reducing surgeries have proved successful in reducing breast and ovarian cancer 
occurrence.  Previous research focusing on BRCA pathogenic variant carriers found that women 
with BRCA pathogenic variants who underwent risk reducing bilateral mastectomies reduced their 
risk of developing breast cancer by 90% or more (Domchek et al., 2010; Geiger et al., 2005; 
Heemskerk-Gerritsen et al., 2007; Ingham et al., 2013; Ludwig et al., 2016; Meijers-Heijboer et 
al., 2001; Rebbeck et al., 2004). 
To reduce the risk for ovarian cancer, a woman who has a BRCA pathogenic variant may 
have a risk-reducing salpingo-oophorectomy (RRSO).  This typically occurs after 35-40 years of 
age for BRCA1 and by 40-45 years of age for BRCA2 or after she has completed her family.  This 
risk-reducing surgery not only decreases the risk of ovarian cancer in BRCA pathogenic variant 
carriers, but also decreases mortality (Domchek, 2019; Domchek et al., 2010; Kauff et al., 2008; 
Rebbeck et al., 2009).  Rebbeck and authors found that the relative risk of ovarian and other 
gynecologic cancers after RRSO was 0.04 (95% CI 0.01 – 0.16), while Kauff and authors found 
that the relative risk of breast and ovarian cancer could be as high as 0.25 (95% CI 0.08 – 0.74) 
(Kauff et al., 2008; Rebbeck et al., 2002).   
1.2.6 Reproductive Choices 
The challenge with adhering to risk reducing guidelines for women with BRCA pathogenic 
variants is that at the point that surgery is discussed, some women may not have started their 
families, or are unsure if they are finished.  This can lead to difficult discussions as the woman 
must balance their desire for family completion with their own risk reduction measures.  The 
United States Preventive Services Task Force recommends guidelines that state RRSO should be 
11 
performed after childbearing is completed or at 35-40 years of age for BRCA1 pathogenic variant 
carriers or at 40-45 years of age for BRCA2 pathogenic variant carriers(Force et al., 2019).  Women 
who discover their high-risk status while their families are incomplete are faced with making a 
decision about this risk-reducing surgery.  After the diagnosis of a BRCA pathogenic variant, 
women who already have children may be less likely to desire additional children than non-carriers 
(Smith et al., 2004).  Subsequently, women who have not had children yet are significantly more 
distressed about treatment-related infertility, even ten years after diagnosis (Camp-Sorrell, 2009; 
Canada et al., 2012).  This concern may be compounded when discussing the implications of a 
positive result for future and current children (Lynch et al., 2006; Speice et al., 2002). 
Women without children are often more concerned about future childbearing (Brunstrom 
et al., 2016; Hoskins et al., 2008; Patenaude et al., 2006).  Decision‐making conflict surrounding 
the timing of risk-reducing surgery and childbearing has been commonly expressed by women 
who are young adults, and is a particularly distressing topic for those who feel they are too young 
to be considering such decisions (Brunstrom et al., 2016).  For women in partnered relationships, 
an awareness of their own cancer risk increases the complexity of decision-making about the 
timing of pregnancy.  (Hoskins et al., 2008).  Bearing young children who might have a heightened 
risk of cancer raises challenging issues for partners who are discussing surveillance and maternal 
life expectancy (Hamilton, 2012; Hoskins et al., 2008; Werner-Lin et al., 2012).  Risk perception 
for mothers appears strongly linked to their parenting role. Several studies found that young 
women's greatest concern was the possibility of leaving children motherless, especially for women 
who had experienced the death of their mother (Brunstrom et al., 2016; Hamilton, 2012; Hoskins 
et al., 2008; Werner-Lin, 2008; Werner-Lin et al., 2012).   
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1.2.6.1 Preimplantation Genetic Diagnosis 
For women who choose to undergo prophylactic surgery before their family plans are 
completed, decisions need to be made about whether they want their children to be biological, and 
if so, free of the BRCA pathogenic variant (Woodson et al., 2014).  Preimplantation genetic 
diagnosis (PGD), as part of the IVF process, allows for the selection and transfer of unaffected 
embryos that begins with standard IVF.  Following fertilization, embryos are tested for the 
pathogenic variant.  Embryos without a BRCA pathogenic variant are reserved for implantation. 
Clinical and moral dilemmas arise when all embryos are affected with a BRCA pathogenic variant 
or if the pathogenic variant cannot be determined.  In situations where the couple only has affected 
embryos that can be used, some couples may elect not to transfer any, if the concern for their future 
offspring having a BRCA pathogenic variant outweighs the desire for biological children.(Herlihy, 
2018).  If one parent is a carrier, consideration may be given to consider using donor ova or sperm 
(Lin et al., 2017; Murray, 2005).   
  Previous research has identified that the use of PGD for BRCA pathogenic variants is 
growing and has become the most common indication in some settings, but the awareness 
regarding its availability varies among countries and is still low (Derks-Smeets et al., 2014b; 
Gietel-Habets et al., 2017; Gietel-Habets et al., 2018a; Gietel-Habets et al., 2018b; Quinn et al., 
2009; Quinn et al., 2010b).  Governmental regulation of PGD varies among countries. In France, 
the Netherlands, and the United Kingdom, the use of PGD is regulated by the government and is 
case-specific. A BRCA pathogenic variant is one of the most frequent indicators for PGD, 
consequently women in those countries would have positive opinions regarding PGD. In the 
United States, the use of PGD is not regulated. As a result, it may be used at the discretion of 
fertility specialists and their patients. Infertility specialists, OB/GYN’s, geneticists and genetic 
counselors prioritize the needs of patients when assisting with the decision for whom PGD should 
be used (Bayefsky, 2018).  A recent survey of 1081 BRCA pathogenic variant carriers highlighted 
that patients are supportive of reproductive counseling, with 59% stating that PGD should be 
offered(Chan et al., 2017). 
1.2.6.2 Cryopreservation Techniques 
Established cryopreservation techniques include the freezing of embryos and oocytes and 
the use of in-vitro fertilization (IVF).  These techniques are associated with a high likelihood 
of successfully generating offspring.  Other options, such as the use of a gestational carrier 
or adoption, are also viable options for women looking to complete their families under the 
constraint of being a high-risk pathogenic variant carrier(Chan et al., 2017; Derks-Smeets et 
al., 2014b; Donnelly et al., 2013b; Fortuny et al., 2009; Friedman et al., 2005; Gietel-Habets 
et al., 2017; Insogna et al., 2016; Mor et al., 2018; Pellegrini et al., 2014; Quinn et al., 2010b; 
Rubin et al., 2014; Woodson et al., 2014).  In addition to family planning, parents are 
confronted with the question of preventing their children from inheriting the pathogenic 
variant. Since carrying a BRCA pathogenic variant is associated with an autosomal 
dominant inheritance pattern, the probability of transmitting a pathogenic variant to each 
offspring is 50% (Gietel-Habets et al., 2017).  This high probability is one of the main reasons 
for undergoing genetic testing (Meiser et al., 2006; Pasacreta, 2003).   
For women who do not have a preference as to whether the child is biological or 
not, adoption is an option that they can pursue.  For those who wish for their children to be 
biological, they might choose between using a surrogate after risk-reducing surgery, or IVF.  
Women who 
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wish for their children to be free of a BRCA pathogenic variant must further decide about the use 
of PGD or IVF. 
Embryo cryopreservation following in vitro fertilization is the most widely used 
and available method of fertility preservation (Farland et al., 2014).  Cryopreserved, thawed 
embryos are used in approximately 20% of all assisted reproductive technology cycles.  Live 
birth rates occur in 45% of patients under the age of 35.  In this method, ovum are removed 
and combined with sperm to form embryos, which are frozen.  Embryos can be thawed and 
placed in the uterus when decision-making is complete, and the woman is ready for 
childbearing.  Another opportunity is ova freezing, a process where ova are extracted, frozen, and 
stored, for future fertilization.  
A surrogate is a woman who agrees to carry a pregnancy for another woman.  The 
intended mother and father provide the egg and sperm.  IVF is used to create embryos, which are 
transferred for implantation.  Adoption is another option for women who want to proceed with 
risk-reducing surgery.  Women may also make the decision to not have children.   
Ethical and moral dilemmas arise when all the embryos are affected 
with a BRCA pathogenic variant, or it is unable to be determined if the embryos 
carry the BRCA pathogenic variant.  The ethical question is whether the burdens of 
carrying susceptibility genes are so great for the child and parents that the burdens of IVF to 
screen embryos to avoid giving birth to affected children are justified (Robertson, 2003). These 
moral dilemmas include cases where couples have only affected embryos and they decide to 
discontinue the process when the concern for their future offspring having a BRCA pathogenic 




Decision-making is a broad term that applies to the process of making a choice between 
options in of action (Thomas et al, 1991).  In decision theory, when making decisions while dealing 
with uncertainty, if information about the best course of action arrives after making a fixed 
decision, the human response of regret is often experienced (Bell, 1982).  Making decisions under 
uncertain circumstances is especially relevant for women who are BRCA positive.  Much research 
has focused on decision-making in regards to the surgical decisions as well as the decision to 
undergo genetic testing in women who have a known family history of breast or ovarian cancer 
(Brunstrom et al., 2016; Cherry et al., 2013; Finch et al., 2012; Garcia et al., 2014; Hartmann et 
al., 2016; Hesse-Biber, 2014; Hoskins et al., 2013; Howard et al., 2009; Kim et al., 2013; Kim et 
al., 2015; Mai et al., 2017; Singh et al., 2013; Watts et al., 2012; Westin et al., 2011).   
Several qualitative studies focusing on women with a BRCA pathogenic variant have laid 
the groundwork for future research.  Women are reported to face complex decisions regarding 
reproduction, when learning their pathogenic variant status.  Women in committed relationships 
placed an emphasis on pregnancy and having as many children as desired before undergoing the 
risk-reducing surgery(Dean, & Rauscher, 2017a; DiMillo et al., 2013; Donnelly et al., 2013b; 
Ormondroyd et al., 2012a; Rowland et al., 2016). Women with a BRCA pathogenic variant 
experience urgency to have children by the age of 35, but when that is not possible, they consider 
extending their preventive surgery timeline in order to bear children despite their own personal 
cancer risk (Hamilton et al., 2016; Quinn et al., 2010b; Werner-Lin, 2008; Woodson et al., 2014; 




1.2.7.1 Individual Factors and Reproductive Decision-Making 
Various factors have been shown to influence patients’ decision-making, especially 
pertaining to family formation.  Age contributes significantly to a woman’s decision to reproduce.  
Women who are older and childless place a greater emphasis on getting pregnant and having as 
many children as desired (Donnelly et al., 2013b; Gietel-Habets et al., 2017).  This is especially 
true in women with a BRCA pathogenic variant, since after undergoing surgery that renders them 
infertile, they are unable to have biological children.  Marital status also plays a role. Women 
without partners reported that knowledge of a BRCA pathogenic variant influenced 
their decisions regarding marriage (Chan et al., 2017; Hamilton, 2012; Hoskins et al., 2008; 
Werner-Lin et al., 2012).  Forty percent had a greater desire to be married and fifty percent felt 
more pressure to be married after learning their BRCA pathogenic variant status.   
  
1.2.7.2 Emotional States and Reproductive Decision-Making 
Reproductive decision-making is highly individualized and difficult.   It can affect the 
decision makers negatively, resulting in conflict or regret (Derks-Smeets et al., 2014a; 
Ormondroyd et al., 2012b).  Previous research has demonstrated that female BRCA carriers seek 
assistance for reproductive decision-making (Quinn et al., 2010a).  Specifically, they identified 
themes concerning the psychosocial impact of carrying a BRCA pathogenic variant, including 
feelings of guilt about passing the pathogenic variant to current and future children.  Young women 
with a BRCA pathogenic variant experienced a broad range of intense feelings (Hamilton et al., 
2010; Hoskins, & Werner-Lin, 2013; Werner-Lin, 2008; Young et al., 2017).  Decision-making 
was not easy and did not occur quickly. This is consistent with previous qualitative research 
highlighting the challenges facing this population (Hamilton, & Hurley, 2010).  Several other 
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studies identified motives and considerations that played a role in the decision‐making process 
(Dekeuwer et al., 2013; Derks-Smeets et al., 2014a; Donnelly et al., 2013a).  To mitigate decisional 
conflict and regret, it was important for couples to make an informed decision.  Counselling should 
help couples obtain relevant information and make a methodical and deliberate decision (Jackson 
et al., 2008; van den Berg et al., 2005).  Emotions play an important role in decision, but it is 
unclear which emotions are predominant. Acknowledging these emotions can guide nurses to 
recognize patient concerns, discuss healthcare issues and provide the decision support needed for 
this vulnerable population. 
1.2.8 Transactional Model of Stress- Appraisal of Life Events scale 
The Appraisal of Life Events (ALE) scale was developed in response to the need to 
measure primary appraisals based on of the Transactional Model of Stress.  In this model by 
Lazarus and Folkman, stressful experiences are presented as person-environment transactions, in 
which the impact of an external stressor is mediated by the person’s response to the stressor 
(Lazarus, 1987).  According to Lazarus and Folkman, the way that people appraise their stressors 
is related to the choice of coping strategies.  An appraisal is defined as ‘a cognitive predisposition 
to appraise future events that triggered the emotion (Lerner, & Keltner, 2001).  Patterns of 
cognitive appraisals along dimensions of emotion provide a basis for comparing and contrasting 
discrete emotions (Ferrer et al., 2013). When individuals confront a stressful situation, primary 
and secondary appraisals are initiated (Lazarus, 1991).  In primary appraisal, a person considers 
the quality and the nature of the stimulus event and the relevance of that event to themselves. 
When a stressor is appraised as requiring a coping response, individuals evaluate their resources 
and abilities to cope with the stressor.  This is known as secondary appraisal (Lazarus, 1987).  An 
appraisal driven approach allows one to systematically examine the effects of emotions on 
decision-making.  Basic dimensions are believed to underlie primary appraisals, such as threat, 
challenge and loss/benefit.  This study will investigate emotions influencing reproductive decision-
making. 
The ALE scale was developed to allow respondents to reflect on the impact of a previously 
experienced event.  Three dimensions underlie primary appraisals: threat, challenge, and 
loss/benefit.  Threat is referred to as the anticipation of psychological or physical damage or loss; 
challenge results from demands that a person feels confident about mastering and loss/benefit 
refers to psychological loss or gain that has yet to occur. 
  A previous study explored the relationship of appraisal, coping and adjustment in 
women and men experiencing infertility concerns.  Evidence supported significant associations of 
the ALE scale with stress measures, and with coping (Bayley et al., 2009).  They found that 
appraisals of infertility as threat or loss were associated with increased infertility-related stress, 
whereas viewing infertility as a challenge was related to increased well-being.  Another study used 
the ALE to assess appraisals in women experiencing infertility.  In this study, Gourounti and 
colleagues used the ALE and found that loss and threat were two factors experienced by 
individuals experiencing infertility (Gourounti et al., 2010).      
1.3 Innovation 
Previous research has focused on the emotional distress experienced by women undergoing 
genetic testing for a BRCA pathogenic variant (Bredart et al., 2013; Hamilton, & Hurley, 2010; 
Mella et al., 2017).  No research has explored the relationship between emotions and reproductive 
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decision-making in women with a BRCA pathogenic variant.  Since these women face 
difficult decisions with limited time it is critical to focus on emotions that are key to decision-
making.  This exploratory study should lead to future research that will address how complex 
emotional states are associated with reproductive decision-making.
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2.0 Research Design and Methods 
2.1 Design 
This exploratory, descriptive, IRB Approved study is designed to describe the association 
between emotion and reproductive decision-making in women who have been tested positive for 
a BRCA pathogenic variant.  A secondary data analysis will be conducted using the Cancer Family 
Registry (CFR), housed at the Cancer Genetics Program at UPMC Magee-Womens Hospital.  The 
CFR serves as a depository of data that can be used by researchers (Institutional Review Board) 
approval.  Most information in the Registry is self-report.   
The principal investigator and co-investigators of the Cancer Family Registry have 
approved this study to collect data retrospectively and prospectively. 
2.2 Sample and Sampling Procedures 
2.2.1 Sample Selection 
374 women with a known BRCA pathogenic variant are enrolled in the Cancer Family 
Registry at UPMC Magee-Womens Hospital.  Women included in this database have been 
contacted by a questionnaire regarding their interest in participating in future research studies.  The 




Inclusion Criteria.  1) Women 18 years of age and older, 2) Women who have a known 
BRCA pathogenic variant, confirmed by genetic testing and 3) Literate English speaker with 
telephone access. 
2.2.2 Sample Size Justification 
The CFR was established to enroll individuals who have been found to carry a genetic 
predisposition to cancer, or a personal or family cancer history suggestive of a genetic 
predisposition.  The original parent sample contains 374 individuals from the CFR who have a 
BRCA pathogenic variant.  Prior to this study, individuals who were part of the Registry were 
mailed a follow-up questionnaire to 1) assess interest in being a continued part of the Registry and 
other studies and 2) update any demographic or personal information from when they were 
consented to the Registry.  75 individuals with a BRCA pathogenic variant responded to the 
mailing.  93 mailings were returned as undeliverable.  Based on the response rate from these 
follow-up surveys, we will expect approximately a 40% response rate for the current survey.  Thus, 
the sample size is estimated to be 75 subjects available for the analysis of all aims.  This 40% 
response rate was chosen as a conservative measure because studies that have been performed 
previously in this population have found typical response rates to be between 40-50%. The 
distribution of BRCA1 vs BRCA2 in the CFR is approximately 58% BRCA1 pathogenic variant 




2.2.3 Projected Precision of Estimators 
When estimating precision for Aim 1, since the aim is a descriptive one, proportions will 
be estimated.  The sample size is fixed at 75 individuals.  When estimating continuous variables, 
the precision would be 0.23σ with a two-sided confidence interval and a standard deviation of 
1.00.  When estimating categorical variables, with a fixed sample size of 75, a two-sided 
confidence interval of 95% and a standard deviation of 1.00, the margin for precision would be 
0.113. 
Specific Aims #2 and #3 explore associations.  When exploring associations, identification 
of precision when estimating correlation coefficient would be calculated.  The precision will be 
dependent on the size of the correlation (see Table 2).  If there is a small correlation (0.1), the 
margin of precision would be expected to be 0.225.  If there is a medium correlation, the margin 
of precision would be expected to be 0.21 and finally, with a large correlation, the margin of 
precision would be expected to be 0.175.         
Aims #4 and #5 would use the logistic regression model to detect the interaction terms and the 
relationship of emotional states and reproductive decision-making.   






















r = 0.0 
0.950 75  0.345 0.173 -0.500 -0.653 -0.308 0.454 
0.950 75  0.415 0.207 -0.300 -0.493 -0.078 0.454 
0.950 75  0.450 0.225 -0.100 -0.320 0.130 0.454 
0.950 75  0.454 0.227 0.000 -0.227 0.227 0.454 
0.950 75  0.450 0.225 0.100 -0.130 0.320 0.454 
0.950 75  0.415 0.207 0.300 0.078 0.493 0.454 





2.2.4 Sampling Procedures 
Individuals were mailed a study packet containing an introductory letter, a consent form, a 
demographic and history questionnaire and an Appraisal of Life Events scale survey.  Individuals 
were asked to complete the signed consent form and return it to the PI with study information if 
they are interested in participating.      
2.2.5 Recruitment Procedure 
The recruitment process for this study is shown in Figure 2.  Individuals who met the 
inclusion criteria were emailed a study packet consisting of an introductory letter, a consent form, 
a demographic and history questionnaire, and an Appraisal of Life Events scale.  The participants 
were asked to read the consent form and the introductory letter before completing the paperwork.  
Upon return of the signed consent form, demographic and history questionnaire, and ALE scale, 
the participant was mailed a copy of their consent form, along with a thank-you note and a $20 
payment.  The data received from the participants were entered into Qualtrics and verified by an 




































Figure 2 Study Flow Chart for Recruitment 
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Table 2 Variables and Level of Measurement 
Variable Level of Measurement Definition 
Age Continuous, ratio Single number in complete 
years 
Age at Diagnosis of BRCA 
pathogenic variant 
Continuous, ratio Single number in complete 
years 
Race Nominal  American Indian, Alaska 
Native, Asian, Black or 
African-American, Native 
Hawaiian or Other Pacific 
Islander, White 
Ancestry Nominal Maternal or Paternal self-
report 
Marital Status Nominal  Never married, married or 
living with a partner, 
separated, divorced, widowed 
Number of Children Continuous, ratio Single whole number 
Family History of Breast 
and/or Ovarian Cancer  
Binary  Yes or No 
Reproductive Decision-
making  
Dichotomous, nominal  “Are you finished having 
children’ measured as Yes or 
No 
Emotional States Approximate, interval  Rating of emotions including 
loss, threat and challenge 
BRCA pathogenic variant 
status  
Categorical, dichotomous BRCA1 or BRCA2 
2.3.1 Instrumentation 
Sociodemographic form. This form was designed to collect participants’ demographic 
information on current age, age at diagnosis, race, ethnicity, marital status, number of children and 
family history of breast and/or ovarian cancer.  These items are self-reported from the Cancer 




continuous ratio variable measured by a single number self-reported in complete years.  Age at 
diagnosis of BRCA pathogenic variant will be a continuous ratio variable measured by a single 
number in complete years.  Race will be a nominal variable, defined as American Indian, Alaska 
Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander and White.  
Ancestry will be the self-reported ancestral background of the individual, reported nominally as 
both the maternal and paternal ancestry (e.g. German, Croatian, Irish).  Marital status is a nominal 
variable and will be defined as never married, married or living as married (with a partner), 
separated, divorced, or widowed.  Number of children will be a continuous ratio variable measured 
by a single number and family history of breast and/or ovarian cancer will be a binary variable, 
measured as yes or no.  This information will be obtained from the data collection form.    
Reproductive Decision-Making. Reproductive decision-making will be measured as a 
dichotomous, nominal variable measured by the single question “are you finished having 
children?” with the responses being either “yes” or “no”.   
Emotional States.  Emotional states will be measured by the Appraisal of Life Events scale 
(Ferguson et al., 1999).  Developed in 1999 in the United Kingdom by Eamonn Ferguson, Gerald 
Matthews and Tom Cox, the Appraisal of Life Events scale has been used in various studies 
including women experiencing infertility, maternal coping with fetal anomalies and examining the 
relationship of coaching behaviors in football (Gourounti et al., 2010; Horsch et al., 2013; Peter et 
al., 2014).  The items on the Appraisal of Life Events scale are measured according to dimension.  
There are 32 response items, 16 in each of two categories, asking to what extent an adjective 
describes or described an event.  In the case of this scale, the event is making a family planning 
decision under a BRCA diagnosis.  Each item is ranked on a scale from 0-5.  These measures will 




individual items will correspond to one of the dimensions: threat, loss/benefit or challenge.  The 
higher the score, the higher the appraisal of threat, challenge or loss/benefit respectively.  These 
three dimensions have demonstrated good internal reliability- Cronbach’s α of threat = 0.82, 0.85, 
0.86; challenge = 0.87, 0.85, 0.85 and loss/benefit = 0.75, 0.82- respectively (Gourounti et al., 
2010; Horsch et al., 2013; Peter et al., 2014). 
BRCA pathogenic variant status.  BRCA pathogenic variant status will be recorded from 
the Cancer Family Registry and measured as a categorical, dichotomous variable.  The responses 
will either be BRCA1 or BRCA2.  The distribution of BRCA1 and BRCA2 is 58% and 42% 
respectively in the Cancer Family Registry.       
2.4 Procedures for Data Collection 
2.4.1 Data Collection 
Upon receipt of the participant questionnaires, data will be entered into a Qualtrics-based 
electronic database by the study PI and double checked by the undergraduate student research 
assistant using direct data entry.  Qualtrics allows for data merging and transfer to a single file 





2.4.2 Data Management 
IBM Statistical Package for the Social Sciences for Mac (Version 24, IBM, Inc., Armauk, 
New York, 2015) will be used for data management.  Data will be entered into the database and 
visually verified by a member of the research team.  All data will be checked and corrected through 
medical record review and by a member of the research team.  Once when data are fully verified, 
variables and values will be labeled, and missing values will be identified to create the data files 
for analysis.  All data will be stored in a password-protected computer and the locked office of the 
PI for this study.  All personal identifiers for the data will be stored in a separate, password 
protected computer in a locked office.  All data analysis will be performed using SPSS. Statistics 
with p-value of less than or equal to 0.05, two-tailed, will be determined to be statistically 
significant. 
2.5 Data Analysis  
2.5.1 Preliminary Data Analysis 
2.5.1.1 Descriptive Statistics  
Descriptive and exploratory analyses will first be performed using SPSS software to 
identify any data anomalies (missing data or outliers that may be a result of data entry error) that 
might invalidate findings of the primary aims analyses to be conducted.  To confirm external 
validity, sample characteristics will be compared to what is currently known in the literature about 




For continuous variables, appropriate descriptive statistics will be computed to describe 
sample characteristics and determine observed variable distributions.  For categorical variables, 
frequency distributions will be examined to ensure adequate category size.  Pairwise correlations 
will be calculated to summarize bivariate associations between variables.  For categorical 
variables, frequency counts and percentages will be reported.  For the central tendency and 
dispersion for categorical variables, mode and range will be reported for nominal variables and the 
median and interquartile range will be reported for ordinal variables.  For continuous variables, we 
will describe central tendency as means and dispersion as standard deviations for normally 
distributed data.  
If the interval and ratio-scaled variables are non-normally distributed, median and semi-
quartile range (SQR) or inter-quartile range (IQR) will also be computed as an alternative to mean 
and standard deviation (SD). The amount and pattern of missing data will be explored and an 
appropriate imputation strategy, such as stochastic regression or multiple imputation will be 
performed. Cases with standardized scores (𝑧𝑧-scores) exceeding the absolute value of 3.29 (p < 
.001, two-tailed test) will be considered as potential univariate outliers. In addition to inspection 
of 𝑧𝑧-scores, histograms, box plots, and normal probability plots will be used to identify univariate 
outliers. To reduce the influence of outliers, identified univariate outliers from continuous type 
interval/ratio scaled variables will be transformed to the next highest/lowest (non- outlier) values 
plus one-unit increment higher/lower.   
The independent variable of emotional states, which is a continuous, interval variable, will 
be measured by the Appraisal of Life Events (ALE) scale.  Frequency distributions will be 
generated to determine frequency counts and percentages.  Central tendency will include 




appears to be non-normally distributed, outliers will first be examined.  If the data appears skewed, 
extreme high or low values will be removed.  The dependent variable of reproductive decision-
making is a dichotomous, nominal variable.  Frequencies will again be used to determine 
frequency counts and percentages.  For the moderator variable of BRCA pathogenic variant status, 
frequencies will once again be used to determine frequency counts and percentages due to the 
dichotomous nominal nature of the variable.   
2.5.1.2 Data Screening 
Data accuracy (meaningfulness of the data) and completeness will be checked at the time 
of data collection and data entry to ensure quality of the data.  Data coding and data entry will be 
rechecked to ensure that no discrepancies exist.  Pattern of missingness among data will be 
checked (look for missing completely at random).  Univariate and multivariate outliers will be 
checked using z-scores and Mahalanobis distance.  To check to see if cases will be statistically 
significant, the standard deviation will be used.    
2.5.1.3 Treatment of Missing Data 
The first step for dealing with missing data is to observe patterns and determine if the data 
are missing consistently or missing at random.  If missing values are concentrated around a few 
variables that are not critical to the analysis, these missing values are highly correlated with each 
other, or they are less than 5% of the sample, then they can be dropped (Osterlind et al., 2001).  
However, ‘non-randomness’ methods should be used to preserve all cases.  If there are missing 
values throughout the cases and variables, an option could be to utilize data imputation, using prior 
knowledge to insert mean values.  If the missing values are stochastic, we can consider using 




missing data as data using a dummy variable with complete cases as 0 and missing cases as 1.  The 
mean can then be inserted for missing values and analyzed. 
2.5.1.4 Outlier Assessment 
For the dichotomous variable, reproductive decision-making, and the demographic 
variables of race, ethnicity, ancestry, marital status and current occupation, univariate outliers need 
to be examined using frequency distributions.  For the continuous variables, age, number of 
children and the ALE, univariate outliers will be determined by calculating and examining the z-
scores.  Any cases with z-scores greater than 3 are potential outliers.  Histograms can be used to 
visually screen for univariate outliers, which would be seen as ‘unattached’ to the rest of the 
distribution.  Box plots will be used to screen for outlying or extreme values for continuous type 
variables, since observations typically center around the median.  Cases that are far away from the 
box are viewed as extreme cases or outliers (Osterlind et al., 2001).   
When considering the pairs of continuous dependent variables and continuous independent 
variables, bivariate plots between variables or scatterplots can be used to determine the outliers.  
The Mahalanobis distance, which is the distance of a case from the centroid of the remaining cases, 
can also be calculated (Mertler et al., 2016).  Creating interaction terms would also be important 
to examine the effects of emotional states and individual factors on reproductive decision-making. 
In regression models, the influence of the outliers must be considered after identifying and 
describing outliers after model fit by examining Cook’s D (Chatterjee et al., 2013)  This measures 
how much the residuals have changed if a particular case has been excluded.  Data points that have 
either high leverage and large residuals greater than 3 need to be further investigated (Chatterjee, 
& Hadi, 2013).  Another influence diagnostic to consider is using the DFBETA.  In using this 
statistic, any values larger than 2/sqrt(n) in absolute value or greater than 1 are considered highly 
influential.  Studentized residual may also be used to determine outliers for values greater than 3. 
These outliers may also exert undue influence on the regression results.  Outlier assessment will 
also be completed post-model fit.  For all fitted models, we will conduct residual analysis and 
assessment of influence diagnostics in terms of (1) the predicted values of potential influential 
observations, (2) regression coefficients, and (3) the standard errors for regression coefficients. 
For all fitted models, we will conduct residual analysis and assessment of influence 
diagnostics in terms of (1) the predicted values of potential influential observations, (2) regression 
coefficients, and (3) the standard errors for regression coefficients.  
2.5.1.5 Checking Assumptions 
 The underlying assumptions for a binary logistic regression include: 1) The dependent 
variable of reproductive decision-making must be binary; 2) Logistic regression requires the 
observations to be independent of each other.  Observations should not come from repeated 
measurements or matched data; 3) There should be no outliers in the data.  This can be 
assessed by converting the continuous predictors to z-scores and removing any value below 
-3.29 or greater than 3.29; 4) There should be little to no multicollinearity among the 
predictors.  This can be assessed by using a correlation matrix among the predictors; 5) There 
should be a linear relationship between the continuous predictor and the logit transformation 
of the dependent variable.  Testing for linearity of the logit must also occur.  The assumption of 
linearity in logistic regression assumes that there is a linear relationship between continuous 
predictors and the logit of the outcome variable. This assumption can be tested by looking at 
whether the interaction term between the predictor and its log transformation is significant.  
Any interaction that is significant will indicate that the main effect has violated the 
assumption of linearity of the logit. 
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 After the data are screened for accuracy and completeness, appropriate assumptions 
of study variables will be checked for all statistical tests.  Assumptions of normality for each 
variable will be assessed through observation of test statistics including skewness and 
kurtosis, as well as graphics such as histograms, scatter plots and normal Q-Q plots.  
Residual plots and bivariate scatter plots between study variables will be examined for 
linearity. In order to check homoscedasticity, the Levene’s test and scatter plots will be 
assessed to determine if all data points of the study variables cluster around the horizontal line. 
In testing multicollinearity for regression models, the tolerance and variance inflation factors 
(VIF) will be examined among variables. A VIF value near 10 or greater than 10 and a small 
tolerance value will be considered as an issue for multicollinearity. No multicollinearity and 
heteroscedasticity should be observed among study variables.  
2.5.1.6 Multicollinearity 
Multicollinearity can be determined using a correlation matrix among the predictor 
variables.  For simple multicollinearity cases, if the correlations coefficients among the 
independent variables are less than 0.80, then this assumption can be met (Osterlind et al., 2001; 
Schroeder et al., 1990).  Another way to determine if there is multicollinearity among the predictor 
is to examine the VIF- the Variance Inflation Factor.  The VIF’s of a linear regression indicates 
the degree that the variances in the regression estimates are increased due to multicollinearity.  A 
VIF of 1 represents the absence of multicollinearity.  VIF values of 10 or more suggest serious 
multicollinearity and the greater the VIF, the greater the degree of collinearity.  If multicollinearity 
is found in the data, one solution could be to center the data.  A simpler solution would be to 
identify the variables that are causing the multicollinearity issues and remove them from the 
regression.  Tolerance can also be considered when determining multicollinearity.  Tolerance is 
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estimated by 1-R.  The minimum value of 0.10 will be used as the threshold for tolerance (Osterlind 
et al., 2001). 
2.5.1.7 Transformation of Data 
A binary logistic regression assumes a linear relationship between continuous predictors 
(measured interval or ratio) with the logit of the binary response.  Each of these variables will need 
to be checked to ensure that each one is linearly related to the log of the outcome variable. VIF 
which is a more rigorous approach than correlation coefficient will also be checked. If the VIF 
goes beyond 10, data transformation will be considered (e.g., centering the variables) to reduce the 
impact of multicollinearity. Since logistic regression analyses will be conducted to examine the 
association between emotional states and reproductive decision-making, underlying assumptions 
will also be checked. The normality of sampling distributions will be assessed by either statistical 
(skewness and kurtosis) or graphical (frequency histograms, normal probability plots) methods. 
Box-Tidwell approach (Hosmer & Lemeshow, 1989) will be used to check linearity in the logit 
for a linear relationship between continuous independent variables and the logit transform of the 
dependent variable, reproductive decision-making when using logistic regression.    
  Transformations are dependent on the shape and the degree to which the sample 
distribution diverges from the normal distribution.  To help determine which type of 
transformation to use, a scatter plot will be utilized.   If there is a moderate difference between the 
sample distribution and the normal distribution, a square root transformation will be considered.   
If there is severe distribution, then the inverse transformation will be used (Osterlind et al., 2001).   
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2.5.2 Data Analysis 
The aims of the study will be addressed through the following analytic approaches.  
Specific Aim 1: Describe the distribution of a BRCA pathogenic variant among 
women who are in the Cancer Family Registry (CFR).  
The demographic and history questionnaire will be used to describe the sample of women 
in this study.  Categorical variables will report frequency distributions, frequency counts and 
percentages.  Mode and range will be reported for nominal variables and the median and 
interquartile range will be reported for ordinal variables.  For continuous variables, central 
tendency will be described as means and dispersion as standard deviations for normally distributed 
data.    
Aim 2: Explore the relationship between emotional states and reproductive decision-
making. 
A binary logistic regression will be used to assess Aim 2.  The emotional state items may 
need to be centered and/or scaled.  A centered variable can be calculated by subtracting each of 
the observations from the mean of all observations.  The same data analysis procedures from Aim 
2 will be conducted in Aim 3.   
Aim 3: Explore the relationship between individual factors (age, race, ethnicity, 
marital status, number of children and family history of breast and ovarian cancer) and 
reproductive decision-making.        
A binary logistic regression analysis will be used.  Because the magnitude of the regression 
coefficients in a multiple linear regression equation depends on the unit of measurement of the 
variable, the emotional scale items may need to be centered and/or scaled.  A centered variable 
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can be calculated by subtracting each of the observations from the mean of all observations.  There 
are two types of scaling that can be used: unit-length scaling or standardizing. 
To assess for model fit in both the binary logistic regression model and multiple linear 
regression model, residual analysis and the assessment for influential observations will be 
performed.  Goodness-of-fit tests for the binary logistic regression include examining the Chi-
square goodness of fit test, using the Homer-Lemeshow test to compare the observed and expected 
frequencies of events and non-events, an examination of the ROC curve with cut-off values from 
0-1 and the maximum likelihood ratio test.  Goodness of fit for the multiple linear regression will 
include the R2 and F-test.   
The binary logistic regression results to be reported include: the odds ratio, the 95% 
confidence intervals and the p value.  The multiple linear regression results will report the 
standardized regression coefficient.   
Specific Aim 4: Explore the moderation of BRCA pathogenic variant status on the 
relationship between emotional states and reproductive decision-making.  
A binary logistic regression will be used to explore the moderation of BRCA pathogenic 
variant status on the relationship between emotional states and reproductive decision-making.  
Hierarchal multiple regression will be used to assess the effects of the moderating variable, BRCA 
pathogenic variant status.  To test moderation, we will examine the interaction effect between 
emotional states and BRCA pathogenic variant status.  
Specific Aim 5: Explore the moderation of individual factors on the relationship 
between emotional states and reproductive decision-making.   
Binary logistic regression will be used to determine the relationship of a predictive model 
in reproductive decision-making.  The study model suggests that individual factors could be a 
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moderator between the relationship of emotional states and reproductive decision-making.  To test 
moderation, we will look at the interaction effect between emotional states and individual factors 
and whether such an effect is significant in predicting reproductive decision-making.  The Hosmer 
Lemeshow test will be employed to evaluate the goodness of fit of the model and the Omnibus test 
of model coefficients (traditional chi-square method) will be used to determine the overall 
significance of the predictors in the model.  
2.6 Research Participant Risk and Protection 
2.6.1 Human Subjects Protection 
Human Subject Involvement:  Participants are women aged 18 and older who have been 
identified to have a BRCA pathogenic variant.  Those individuals that do not speak the English 
language were excluded.   
Inclusion of Women:  The sample of this study is only women.  With a specific focus on 
individuals who must make a reproductive decision, this study focused on the recruitment of a 
sample whose gender distribution generally corresponded to the number of individuals who make 
reproductive related decision under the guise of having a BRCA pathogenic variant. 
Inclusion of Minorities:  This study sought to represent racial and ethnic minorities in its 
sample.  No one was excluded from participation in this study based on race or ethnicity.   
Inclusion of Children:  No children are included in this study.  The age limit was set at 18 
years of age with no upper limit.  Subjects younger than 18 were excluded because genetic testing 
for the BRCA pathogenic variant is not performed on individuals younger than 18.      
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Sources of Materials:  Data will be self-reported.  In addition, individual factors will be 
confirmed with the medical records.  All data will be identified by code numbers only (participant 
IDs) and will be stored in secure locations, including locked file cabinets and password-protected 
computers.  Participant ID’s will be linked to participants’ names in a password-protected file that 
is accessible only to the PI and research team.    
Potential Risk and Protection against Risk:  One potential risk is a breach of 
confidentiality.  To protect participants’ privacy, only members of the research team will be aware 
of individuals’ participation in this research study.  Participant names will not be included on the 
paper questionnaires completed.  All data will be kept in secure, locked file cabinets at the School 
of Nursing.  All information will be identified by a study ID number. The information linking ID 
numbers with identifiable information will be kept separate from the research records and will be 
stored under lock and key.  The PI will manage access to the identifiable data; access will be 
provided only to team members who require access for study-related work. All team members 
involved in this study are current in all required research modules.  Individual identities will not 
be revealed in any description or publications of this research, and data will only be presented in 
aggregate.   
Completion of questionnaires by study participants creates a potential risk for inducing 
stress.  Another possible risk of this research study may include stress from having to complete 
the questionnaires. Participants are advised to take a break if the questions induce stress or 
discomfort, they can take a break from completing the questionnaires and do not have to complete 
all individual questions at once.  Study participants are reminded that survey responses are not sent 
to their healthcare providers.  If they experience bothersome emotional symptoms, they should 
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contact their health care team. It is estimated that time to complete the survey is estimated to be 
20-30 minutes. 
Recruitment and Informed Consent:  Participants were recruited from the Cancer Family 
Registry at UPMC Magee-Women’s Hospital.  After identification, the principal investigator will 
assure that individuals meet the study eligibility criteria and are willing to participate. For those 
individuals willing to participate, detailed information regarding the study design and procedures 
(e.g., purpose of study, risk/benefits, nature of questions asked, time commitment) will be provided 
and all questions answered prior to signing consent.  Participants will likely not receive direct 
benefit from participating in the study.  
2.6.2  Importance of Knowledge to be Gained 
Previous research has focused on the emotional distress experienced by women undergoing 
genetic testing for a BRCA pathogenic variant.  No research has explored the relationship of 
emotions and reproductive decision-making in women who are BRCA positive. 
Since these women face difficult decisions along a very tight timeline related to their 
reproductive choices, it is critical to focus on the important emotions that are key to their decision-
making.  Data from the proposed study will provide critical information regarding emotions and 
reproductive decision-making.  This will inform further research leading to successful nursing 
interventions to support women with a BRCA pathogenic variant.   
2.6.3 Summary of Study 
2.6.3.1 Changes to Proposed Study 
This section is intended as a bridge between the proposed study, as approved by the 
committee and the actual study as it was conducted.  These changes, along with the rationale 
for these changes, are provided below.   
Recruitment:  The original focus was revised to include only women who were below the age of 
45 at the time of their BRCA test disclosure.  Through discussion with committee members, it was 
decided that it would be unfair to ask post-menopausal women about their reproductive planning 
since it is likely that they were finished with childbearing.   
Supplemental Material:  Through discussion with the committee, it was decided to add a follow-
up component to the study to garner more thorough information regarding the specific reproductive 
planning that women undertook.  This follow-up questionnaire would involve calling the women 
who sent back their original mailing packet with consent form, and giving them to choice to 
complete the additional questions over the phone, or through a Qualtrics survey link emailed to 
them.   
2.6.4  Conclusions, Implications for Nursing and Future Studies 
Overall, this dissertation study has both strengths and limitations.  This study seeks to 
expand and challenge our current understanding of emotional states, particularly in individuals at 
high genetic vulnerability.  No study has specifically examined the emotional states around 
reproductive decision-making and family planning in women with a BRCA gene mutation.  
Continuing to engage patients in the planning and interpretation of results, and what they mean for 
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their family planning is key to enriching the understanding of the emotional states of these women. 
This design may have limitations in that it only sent one mailing out to participants, as opposed to 
multiple mailings to strengthen the response rate.   
In conclusion, this dissertation provides an increased understanding of the range of 
emotions that impact reproductive decision-making, especially women with increased genetic 
susceptibility and also provides and avenue towards next steps.  Taken together, these findings 
have implications for nursing science as these emotions and its trajectories can be used towards 
identifying those most at risk and implementing interventions that can be used towards proactive 
decision-making around family planning.    
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3.0 Manuscript 1: A Review of Reproductive Decision Making in Women who are BRCA 
Positive 
Presented here is the full-text version of the manuscript accepted for publication, which was 
subsequently published in the Journal of Obstetric, Gynecologic and Neonatal Nursing.  A copy 
of this manuscript can be accessed at: 
https://www.sciencedirect.com/science/article/abs/pii/S0884217520301179?via%3Dihub.   
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3.1 Abstract 
Objective: To synthesize research findings regarding reproductive decision-making 
among women who are BRCA positive.  
Data Sources: PubMed and CINAHL. 
Study Selection: Articles published in English between 2000 and June 28, 2020 about the 
reproductive decision-making of women with a confirmed BRCA1 or BRCA2 mutation.   
Data Extraction: We extracted data on participants, study design, analysis, follow-up, and 
results. We rated studies for quality and applicability by using the Modified Downs and Black 
Checklist and Kennelly's Qualitative Data Analysis.    
Data Synthesis: We included five of 257 screened articles in our synthesis. The total 
sample size of the five studies was 1468 women. The most prevalent factors related to reproductive 
decision-making were the impending decisions regarding childbearing and family choices, 
including decisions about biological children, preventive surgery, PGD and prenatal diagnosis to 
prevent further transmission of a BRCA mutation, and family planning.  
Conclusion: A lack of knowledge exists regarding the reproductive decision-making 
processes of women who are BRCA positive. Understanding this process would provide nurses 
and other clinicians with the knowledge needed to support these women.   
3.2 Introduction 
BRCA1 and BRCA2 genes produce tumor suppressor proteins. The role of these proteins is 




(National Cancer Institute, 2018a). When either of these genes is mutated, the repair work of 
damaged DNA does not occur. Because of the inability to repair DNA, additional genetic 
alterations occur that can lead to cancer. Specific, inherited BRCA mutations increase the risk for 
ovarian and breast cancers. Women who inherit mutations in BRCA1 and BRCA2 tend to develop 
breast and ovarian cancers at younger ages than those without these mutations. These gene 
mutations are responsible for 5% to 10% of all breast cancers and 10% to 15% of all ovarian 
cancers (Heald et al., 2016).  BRCA1, located on chromosome 17 and discovered in 1994, contains 
more than 1,800 variants that cause increased risk of cancer (Nelson et al., 2019b). The BRCA2 
gene, located on chromosome 13 and discovered in 1995, contains more than 1,300 variants 
(Nelson et al., 2019b).  
BRCA mutations are inherited in an autosomal dominant pattern (Julian-Reynier et al., 
2012). Either parent who has a BRCA mutation has a 50% chance of passing the mutation to 
offspring. To date, hundreds of variants have been identified within the BRCA genes.  Women are 
typically not aware that they have BRCA gene mutations until a close female relative is diagnosed 
with breast or ovarian cancer. Many choose to undergo genetic testing as early as age 18 to 
determine their risk. However, cancer risks associated with BRCA gene mutations rarely manifest 
before the late twenties or early thirties. (Stopfer, 2012).  
Women who have BRCA1 mutations have an 85% lifetime risk for breast cancer and a 65% 
lifetime risk for ovarian cancer; women who have BRCA2 mutations have an 80% lifetime risk for 
breast cancer and a 23% lifetime risk for ovarian cancer (Kuchenbaecker et al., 2017a). Because 
of these risks, specific risk reduction strategies are recommended, including salpingo-
oophorectomy at the age of 35 or when childbearing is complete and a bilateral mastectomy 




Gynecology et al., 2017; Daly et al., 2017; see Table 1). Because of the current trend among 
women to postpone childbearing until their 30s, a growing number of women will be diagnosed 
with cancer before they complete their families (Waimey et al., 2015). This has resulted in an 
increased focus on fertility and reproductive choice by women who are BRCA positive and view 
childbearing as a priority (Flink et al., 2017; Hoskins et al., 2014). Unfortunately, many women 
have not yet considered how many biological children they want by the time they become aware 
of risk-reducing guidelines. Subsequently, when these women reach the recommended age for 
surgery, they have lost the window of opportunity to complete their families. Depending on their 
choices, they may have varying levels of regret afterward (Di Prospero et al., 2001; Gietel-Habets 
et al., 2017; Stan et al., 2013; Werner-Lin et al., 2012). 
3.3 Family Planning Options 
Among couples in which one partner carries a BRCA mutation, multiple options for family 
planning are available, including conceiving naturally, pursuing in-vitro fertilization (IVF), or 
deciding not to have children. Fertility preservation options such as embryo cryopreservation, 
surrogacy, and adoption can also be considered (Chan et al., 2017; Derks-Smeets et al., 2014; 
Donnelly et al., 2013; Fortuny et al., 2009; Friedman & Kramer, 2005; Gietel-Habets et al., 2017; 
Insogna & Ginsburg, 2016; Mor et al., 2018; Pellegrini et al., 2014; Quinn et al., 2010; Rubin et 
al., 2014; Woodson et al., 2014).  Couples who have biological children already and those who are 
preparing for biological children may find themselves confronted with the question of preventing 




Preimplantation genetic diagnosis (PGD) as part of the IVF process allows for the selection 
and transfer of unaffected embryos. It begins with standard IVF. After the woman receives 2 weeks 
of hormonal stimulation, which includes two daily injections of follicle-stimulating hormone and 
luteinizing hormone, retrieval and fertilization of ova occur. The fertilized ova are tested for 
mutation after 8 days of development. Embryos without BRCA mutations are reserved for transfer. 
Ethical and moral dilemmas arise when all the embryos are affected with BRCA mutations or status 
cannot be determined. For example, a couple may find that all of their embryos are affected. They 
may decide to discontinue the process if concern for their future offspring outweighs their desire 
for biological children (Herlihy et al., 2018). If the ova or sperm carries a BRCA mutation, 
individuals may use a donor to prevent transmission (Lin et al., 2017).  However, for women of 
certain religious or ethnic backgrounds, the use of IVF with PGD may cause moral distress as it 
allows for the selection and transfer of unaffected embryos only.    
Embryo cryopreservation following in vitro fertilization is the most widely used and 
available method of fertility preservation (Farland et al., 2014). In this method, ova are removed 
and combined with sperm to form embryos that are frozen. Embryos can be thawed and placed in 
the uterus when decision-making is complete, and the woman is ready for childbearing.   
Cost is likely to be a factor in decision-making. Under the Affordable Care Act, insurance 
companies are required to pay for genetic counseling and testing when criteria are met. For eligible 
women, insurance companies cover the entire cost of genetic counseling and BRCA testing with 
no out-of-pocket costs to the individual. However, family planning options, such as PGD and IVF, 
are often not covered by insurance. Insurance plans may offer coverage in selected cases, but the 
cost of multiple cycles of IVF and PGD may exceed $15,000 per cycle. Therefore, lack of 
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insurance coverage and inability to pay the out of pocket costs are barriers for some families 
(Insogna et al., 2017; Drazba et al., 2014; Green, & Weiss, 2013). 
Researchers have examined decisions to undergo genetic testing and the process of 
decision making regarding bilateral salpingo-oophorectomy (BSO) and hysterectomy in women at 
risk for a BRCA mutation and those already diagnosed (Chan et al., 2017; Friedman, & Kramer, 
2005; Garcia et al., 2014a; Garcia et al., 2014b; Hoskins et al., 2014; Pal et al., 2015; Werner-Lin 
et al., 2012).  Despite extensive evidence related to the issues that women with BRCA mutations 
face, reproductive decision-making in this population is not well studied. Therefore, the purpose 
of our review was to synthesize the research literature regarding reproductive decision-making in 
women who have BRCA1 or BRCA2 mutations.    
3.4 Methods 
The integrative review method is an approach that allows for the combination of diverse 
methodologies to reach the goal of comprehensive perspectives on a chosen topic.  The results 
capture the depth and breadth and provide information and potential direction for further research. 
We conducted an integrative review to synthesize data on reproductive decision-making in women 
with a BRCA1 or BRCA2 mutation.       
3.4.1 Literature Selection 
To identify relevant resources, we consulted an expert health science research librarian to 




We searched for original research articles on reproductive decision-making by women with 
BRCA1 or BRCA2 mutations published between 2000 and 2017 and available in English. Inclusion 
years were expanded due to increased available publications on the BRCA mutation. We conducted 
the original search in September 2017 and updated it in June 2020.  This accounted for variant 
terminology and indexing variations identified during phases of search term harvesting and testing. 
Initial search terms used were BRCA (including all deviations), Hereditary Breast and Ovarian 
Cancer Syndrome (HBOC) reproduction, fertility, and decision-making. We identified additional 
resources through hand searches of relevant resources and examination of the reference lists of the 
articles returned from the initial search.   
Articles that addressed the reproductive decision-making process, included women with 
confirmed BRCA1 or BRCA2 mutations, and were published between January 2000 and June 28, 
2020 in English were included.  We excluded studies that focused on women with 
unknown BRCA1 or BRCA2 mutation status or who were in the process of being tested for the 
mutation. Because the focus of our review was reproductive decision-making, we only included 
studies related to that topic.  
3.4.2 Search Outcome and Study Selection 
The search and study selection processes are depicted in the Preferred Reporting Item for 
Systematic Reviews and Meta-Analysis (PRISMA) flowchart (Figure 1). The preliminary search 
yielded 257 potentially relevant records. After duplicates were removed and exclusion criteria 
applied, we reviewed the titles and abstracts of 67 records from which 62 records were excluded, 




The remaining five articles received full-text review, and the two reasons noted for 
exclusion were unknown BRCA mutation status and final decision-making outcome was not 
fertility related.  Despite relatively broad inclusion criteria, only three of the five articles that 
received full review met the inclusion criteria. Hand searches of reference lists and forward citation 
searches of the three selected articles yielded two additional articles for analysis, resulting in a 
total of five articles for our review.  
3.4.3 Data Extraction and Synthesis 
We extracted and tabulated the following data for the five selected articles: authors, study 
design, purpose, inclusion criteria, sample, measures, and results (see Table S2). After we 
reviewed all articles, the first author (ES) read and analyzed each and noted themes and 
characteristics. The second, third, and fourth authors (JDJ, CD, SW) reviewed all themes and 
discussed and agreed upon the findings. 
3.5 Results 
A total of 1468 women participated in the five included studies. The largest sample size 
was 1081 participants (Chan et al., 2017) and the smallest was 20 (Dean & Rauscher, 2017). One 
study was conducted in the United Kingdom and one in the Netherlands. The remaining three 
studies were conducted in the United States. The average age of participants in the studies was 





3.5.1 Measurement of Reproductive Decision-Making 
How reproductive decision-making was measured varied across the studies. Authors 
used semi-structured interviews to discuss the effects of BRCA1 and BRCA2 mutations on life 
decisions, especially related to plans to have children (Donnelly et al., 2013) and how women 
with BRCA mutations but not cancer diagnosis made decisions regarding family planning (Dean 
& Rauscher, 2017). Cross-sectional surveys were used to determine fertility consultation and 
fertility preservation treatment (Gietel-Habets et al., 2017; Kim et al., 2015). 
We used a modified Downs and Black Checklist (Downs, & Black, 1998; Figure 2) to 
appraise the quality of the three quantitative studies included in our review. Questionnaires were 
used in the three cross-sectional studies; Chan et al. (2017) and Gietel-Habets et al. (2017) used 
literature searches to develop questionnaires, while Kim et al. (2015) engaged reproductive experts 
to develop questions to assess participants’ views of fertility preservation treatments.   External 
validity was high due to the sample sizes in these studies (range 151 to 1081). 
Two of the studies were qualitative, and the researchers used semi-structured interviews 
for data collection in both (Dean & Rauscher, 2017, Donnelly et al., 2013). Figure 3 shows our 
assessment of the two qualitative studies (Dean & Rauscher, 2017; Donnelly et al., 2013) using 
the Guidelines to Evaluate the “Quality and Evidence” of Qualitative Studies, adapted by Joan 
Kennelly (Kennelly, 2011). With the exception of the data analysis category, both studies ranked 
moderate to high in all remaining categories (research design, sampling, data collection, 
findings/results, research value, and research design). Based on the assessment of quality and 
evidence of the studies, we rated one study (Dean & Rauscher, 2017) as ‘fair’ and the other 
(Donnelly et al., 2013) as ‘high’. We identified themes related to reproductive decision-making 




and Awareness of PGD and Prenatal Diagnosis, and Choices and Attitudes Regarding 
Childbearing and Passing Mutation to Offspring. 
Effect on Relationships and Childbearing  
Researchers evaluated the effects that a BRCA mutation had on relationships and 
childbearing (Chan et al., 2017; Donnelly et al., 2013).  Descriptive studies were used to assess 
demographic information and answer questions regarding the influence of BRCA status on 
marriage, relationships, and family planning. Chan et al. (2017) demonstrated that 22% of 1081 
participants reported that knowledge of their carrier status made them more anxious to get married 
while 38% of participants reported that their carrier status influenced the selection of a partner. 
Participants sought partners who were emotionally and financially secure, understood their carrier 
status, and supported their decision-making (Chan et al., 2017). Donnelly et al. (2013) found that 
among 25 women participants, their husbands did not agree about family planning especially if 
they had children from a previous marriage.  These men were reluctant to engage in discussions 
about having additional children with the risk of a BRCA transmission.  For women who were in 
committed relationships and were over 30 years old, the priority was to have children while for 
younger women, the priority was finding the right partner. These findings were consistent across 
studies (Chan et al., 2017; Dean & Rauscher, 2017; Donnelly et al., 2013). 
Acceptability and Awareness of PGD and Prenatal Diagnosis 
Authors of three studies explored the acceptability and awareness of (PGD) and prenatal 
diagnosis (PND) (Chan et al., 2017; Dean & Rauscher, 2017; Gietel-Habets et al., 2017). 
Researchers identified whether the participants were aware of the possibility of PGD or prenatal 
diagnosis, their level of knowledge regarding these two reproductive options, and if they viewed 




reproductive options in the prevention of transmission of the BRCA mutation. Findings of these 
studies indicated that childless women who were younger, had a higher educational level, and 
more immediate child desires were more aware of diagnostic options and cancer risk (Chan et al., 
2017; Dean & Rauscher, 2017; Gietel-Habets et al., 2017). 
Chan and colleagues (2017) found that a personal history of cancer, already having 
children, older age, and type of BRCA mutation were not associated with acceptance of PGD or 
prenatal diagnosis. Of the 1081 women who would choose to use PGD or prenatal diagnosis, 376 
(34.8%) would consider undergoing PGD to reduce the risk of a BRCA mutation transmission and 
600 (55.5%) believed that prenatal diagnosis should be offered to pregnant women who are BRCA 
mutation carriers (Chan et al., 2017). Further, of the 600 women who believe that prenatal 
diagnosis should be offered to pregnant women, only 180 (30%) report that they would actually 
use it themselves (Chan et al., 2017).  Despite these values, few women would consider pregnancy 
termination if the fetus carried a mutation (Chan et al., 2017; Gietel-Habets et al., 2017).  
Choices and Attitudes Regarding Childbearing and Passing Mutation to Offspring  
Some women struggled with knowing they could pass the mutation to their children and 
experienced guilt after learning that they were pregnant (Dean & Rauscher, 2017). These feelings 
of guilt were consistent with the results of Chan et al. (2017) who found that out of 116 women, 
20 (17.2%) would not have children because they were concerned about the risk of transmission 
to their offspring.  Despite the concern of passing mutations to offspring, many women with BRCA 
mutations still want to have children naturally (Chan et al., 2017; Dean & Rauscher, 2017). Few 
researchers have examined women’s attitudes and experiences regarding PGD or prenatal 
diagnosis. Of the 635 women who believe that PGD should be offered to individuals with a BRCA 




families were not complete at the time of BRCA test disclosure, 116 (40.8%) said that the 
knowledge of their BRCA status affected their decisions to have biological children (Chan et al., 
2017) and 50 (17.7%) would pursue fertility treatments. Further, of the 50 women whose families 
were not complete at the time of BRCA test disclosure, 20 (40%) would consider IVF to freeze 
their eggs for future use (Chan et al., 2017). Women who already had biological children were less 
likely to pursue fertility treatments in light of their BRCA status (Chan et al., 2017; Dean, & 
Rauscher, 2017). Despite the small number of women who would choose fertility treatments, the 
majority of mutation carriers, especially those who did not have children and were non-white, 
expressed positive opinions about fertility preservation treatments (Chan et al., 2017; Donnelly et 
al., 2013; Gietel-Habets et al., 2017; Kim et al., 2015).   
3.6 Discussion 
Women diagnosed with a BRCA mutation face difficult decisions about childbearing. 
Results of our integrative review suggest that marriage and relationship status, as well as views 
about the use, acceptability, and awareness of fertility options, affect women’s childbearing 
decision-making. Women with a known BRCA mutation have a sense of urgency in prioritizing 
childbearing over cancer risk management (Chan et al., 2017). 
Some researchers have noted that single women who test positive for a BRCA mutation 
experience urgency to find a partner (Donnelly et al., 2013; Hamilton & Hurley, 2010; Werner-
Lin, 2008). These women desire someone who is emotionally and financially secure, understands 
their mutation status, and is supportive of their reproductive decision-making (Chan et al., 2017; 




than finding a partner (Donnelly et al., 2013; Gietel-Habets et al., 2017). Women with 
a BRCA mutation expressed urgency to bear children if possible before surgery is recommended 
that will decrease their cancer risk but render them infertile. When that was not possible, they 
considered extending their preventive surgery window to bear children despite their increasing 
cancer risk (Chan et al., 2017). We found that women with children were more likely to undergo 
preventive surgery than childless women, analogous to previous research findings from a survey 
of women at increased risk for breast and ovarian cancer, but who were not confirmed as BRCA 
mutation carriers (Howard et al., 2009; Padamsee et al., 2017). Regardless of relationship status, 
a sense of urgency towards childbearing is still prevalent among women since they recognize that 
fertility declines with age (Chan et al., 2017; Dean & Rauscher, 2017; Donnelly et al., 2013). While 
this desire for children can cause strain on relationships, counseling may be helpful for couples to 
assess the risks to both the woman’s health and that of future children against not having a 
complete family (Hoskins et al., 2014).   
We found that childless women who considered PGD tended to be younger with higher 
educational levels and more immediate desires for children (Chan et al., 2017; Donnelly et al., 
2013; Gietel-Habets et al., 2017). However, because PGD provides couples the opportunity to 
select non-BRCA positive embryos, individuals may be conflicted about this choice due to ethical 
or moral dilemmas.  Although few researchers have assessed women’s attitudes and experiences 
regarding PGD, those that have, found that while the majority of women believe PGD should be 
offered to individuals testing positive for a BRCA mutation (Chan et al., 2017), relatively few 
would consider it for themselves (Donnelly et al., 2013; Gietel-Habets et al., 2017).  
Governmental regulation of PGD varies among countries. For example, in France, the 




mutation is one of the most frequent indicators for PGD; consequently, women in those countries 
would have positive opinions regarding PGD. In the United States, the use of PGD is not 
government regulated. As a result, its use is at the discretion of fertility specialists, 
obstetrician/gynecologists, geneticists, and genetic counselors who independently prioritize the 
needs of patients when assisting with the decision for whom PGD should be used (Bayefsky, 
2018).    
Research findings show that women are strongly motivated to do whatever they can to 
control the risk of genetic mutations for their future children (Julian-Reynier et al., 2012; Quinn et 
al., 2010). For most women with BRCA mutations and their partners, the decision to use 
reproductive technologies is far more difficult than previous decisions and they may find 
themselves paralyzed by an inability to move forward (Ormondroyd et al., 2012). 
We found that women with BRCA mutations struggle with the idea that their children may 
inherit the mutation and often have feelings of sadness and guilt. These findings are consistent 
with previous research that has focused on opinions influencing the decision to be tested for 
a BRCA mutation (Hesse-Biber, 2014; Hesse-Biber & An, 2016; Kridli & Austin, 2018; Sankar et 
al., 2006). We also found that knowledge of a BRCA mutation status influenced women’s decisions 
to have children. Findings of our review show that among women diagnosed with a BRCA 
mutation, 25% would pursue fertility treatments and 50% would freeze their eggs for future use 
(Chan et al., 2017; Donnelly et al., 2013). Many women desire to have children naturally, without 
the use of PGD, knowing that the risk of transmission is not eliminated.   
Over 90% of the participants in the studies reviewed were White, although findings of other 
studies suggest that BRCA mutations have comparable prevalence among African-Americans (Pal 




populations. However, there are significant racial/ethnic factors that influence the ability to access 
genetic testing and BRCA risk management interventions.  
3.6.1 Limitations 
The limitations of this study include the exclusion of articles that were not published in 
English and the omission of reviewed papers in which the authors addressed participants’ desire 
for more children.  We feel the addition of these studies would provide key information about 
fertility intentions.  Also, participants of diverse, ethnic groups are not well represented in the 
studies reviewed, and this lack of sample diversity limits the generalizability of our findings. 
3.6.2 Implications 
The most important implication in this study is the recognition that women with BRCA 
mutations, particularly younger women, feel a sense of urgency to complete their families.  These 
challenges provide the recognition that younger women need more support and provides the 
opportunity for nurses and advanced practitioners to offer this support.  These women are in need 
of guidance regarding marriage and family planning and visits and guidelines using well-
established professional guidelines can be useful in addressing these challenges.  In addition, the 
use of evidence-based counseling to develop tailored nursing interventions, including a detailed 
family history, the documentation of these results in the electronic health record, and awareness of 
the Advance Practice Nursing genetic/genomic competencies would be helpful in addressing these 
challenges (Greco et al., 2011; see Table 3).  It is evident that reproductive decision making among 




aspects of women’s reproductive decision making in light of BRCA mutations were not included 
in any of the studies in our review.  Acknowledging these emotions can guide nurses to recognize 
patient concerns, discuss healthcare issues, and provide the decision support needed for this 
vulnerable population.   
3.7 Conclusion 
The paucity of research regarding women’s reproductive decision-making when they have 
BRCA mutations presents an important opportunity for future research. As more women learn their 
genetic breast or ovarian cancer risks, they must grapple with difficult decisions about reproductive 
life planning. The recurring themes from our review included Effects on Relationships and 
Childbearing, Acceptability and Awareness of PGD and Prenatal Diagnosis, and Choices and 
Attitudes Regarding Childbearing and Passing Mutation to Offspring.  The emotional aspects of 
this decision-making are not well understood and require additional study. Identifying the 
emotions and personal values influencing reproductive decision-making will help nurses provide 
psychological support and compassionate, knowledgeable care. Providing women with clear 
guidance and information regarding choices concerning the multiple options available to them is 
paramount. The sensitivity and complexities of these issues and the likelihood that they will require 





Table 3 Table of Recommendations for BRCA1/BRCA2 mutation carriers 
Organization Recommendation(s) 
American College of 
Obstetricians and Gynecologists 
(American College of 
Obstetricians and Gynecologists 
Committee on Practice Bulletins-
Gynecology et al., 2017) 
Risk-reducing bilateral salpingo-
oophorectomy recommended at age 35-40 years for 
BRCA1 carriers and at age 40-45 for BRCA2 carriers 
American Society of Clinical 
Oncology (Tung et al., 2020) 
Preventive, risk-reducing salpingo-
oophorectomy should be performed at the completion 
of childbearing or by the age of 40 
Risk-reducing salpingo-oophorectomy should 
be considered earlier for BRCA1 carriers (before 40) 
than for BRCA2 carriers given the earlier onset of 
ovarian cancer in BRCA1 mutation carriers 
National Comprehensive Cancer 
Network (National 
Comprehensive Cancer Network, 
2019)  
Risk-Reducing salpingo-oophorectomy is 
recommended between ages 35 and 40 years, when 
childbearing is completed, but may be delayed to age 
45 years for BRCA2 carriers if necessary 
Society of Gynecologic Oncology 
(Society of Gynecologic 
Oncology, 2017) 
Risk-reducing bilateral salpingo-
oophorectomy recommended at age 35-40 years for 
59 
BRCA1 carriers and at age 40-45 for BRCA2 carriers 
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Table 5 Essentials of Genetic and Genomic Nursing: Competencies, Curricula Guidelines, and Outcomes (Jenkins, 
& Calzone, 2007) 
Professional Responsibilities Competencies 
• Recognize when one’s own attitudes and values related to genetic and genomic science
may affect the care provided to clients
• Advocate for clients’ access to desired genetic/genomic services and/or resources including
support groups
• Examine competency of practice on a regular basis, identifying areas of strength, as well as
areas in which professional development related to genetics and genomics would be
beneficial
• Incorporate genetic and genomic technologies and information into registered nurse
practice
• Demonstrate in practice the importance of tailoring genetic and genomic information and
services to clients based on their culture, religion, knowledge level, literacy, and preferred
language
• Advocate for the rights of all clients for autonomous, informed genetic- and genomic-
related decision-making and voluntary action
Professional Practice Domain 
Nursing Assessment: Applying/Integrating Genetic and Genomic Knowledge 
71 
• Demonstrates an understanding of the relationship of genetics and genomics to health,
prevention, screening, diagnostics, prognostics, selection of treatment, and monitoring of
treatment effectiveness
• Demonstrates ability to elicit a minimum of three generation family health history
information
• Constructs a pedigree from collected family history information using standardized
symbols and terminology
• Collects personal, health, and developmental histories that consider genetic, environmental,
and genomic influences and risks
• Conducts comprehensive health and physical assessments which incorporate knowledge
about genetic, environmental, and genomic influences and risk factors
• Critically analyzes the history and physical assessment findings for genetic, environmental,
and genomic influences and risk factors
• Assesses clients’ knowledge, perceptions, and responses to genetic and genomic
information
• Develops a plan of care that incorporates genetic and genomic assessment information
Identification 
• Identifies clients who may benefit from specific genetic and genomic information and/or
services based on assessment data Identifies credible, accurate, appropriate, and current
genetic and genomic information, resources, services, and/or technologies specific to given
clients
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• Identifies ethical, ethnic/ancestral, cultural, religious, legal, fiscal, and societal issues
related to genetic and genomic information and technologies
• Defines issues that undermine the rights of all clients for autonomous, informed genetic- 
and genomic-related decision-making and voluntary action
Provision of Education, Care, and Support 
• Provides clients with interpretation of selective genetic and genomic information or
services
• Provides clients with credible, accurate, appropriate, and current genetic and genomic
information, resources, services, and/or technologies that facilitate decision-making
• Uses health promotion/disease prevention practices that:
• Consider genetic and genomic influences on personal and environmental risk factors
• Incorporate knowledge of genetic and/or genomic risk factors
• Uses genetic- and genomic-based interventions and information to improve clients’
outcomes
• Collaborates with health care providers in providing genetic and genomic health care
• Collaborates with insurance providers/payers to facilitate reimbursement for genetic
and genomic health care services
• Performs interventions/treatments appropriate to clients’ genetic and genomic health
care needs
• Evaluates impact and effectiveness of genetic and genomic technology, information,
interventions, and treatments on clients’ outcome
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Figure 3 PRISMA Flowchart on literature search process, strategies and outcomes
Records identified through 
database searching 
























Additional records identified 
through other sources 
(n = 2) 
Records after duplicates removed 
(n = 247) 
Records screened 
(n = 247) 
Records excluded 
(n = 180) 
Full-text articles assessed 
for eligibility 
(n = 67) 
Studies included in integrative review 
(n = 5) 
Full-text articles excluded, with reasons 
(n = 62) 
• BRCA status unknown (n=37) 




(n = 3) 
Qualitative study 
(n = 2) 
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Figure 4 Quality Appraisal of Included Studies Using a Modified Downs and Black Checklist 
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Figure 5 Quality Appraisal of Included Qualitative Studies Using Kennelly's Qualitative Data Analysis 
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4.0 Data-Based Manuscript: The Association of Emotional States on Reproductive 
Decision-Making in Women who are BRCA Positive 
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4.1 Introduction 
Women who live in the United States have a 12% risk of developing breast cancer and a 
2% risk of developing ovarian cancer during their lifetime.  For women who carry a pathogenic 
BRCA1 or BRCA2 variant, one that affects approximately one in 200-400 women living in the 
United States, this risk increases (Kuchenbaecker et al., 2017a; Manickam et al., 2018).  For breast 
cancer, lifetime risk ranges from 55-70% for BRCA1 carriers by the age of 70 and between 45-
70% in BRCA2 carriers.  For lifetime risk of ovarian cancer, the risk ranges from 40-45% for 
BRCA1 and 15-20% for BRCA2 (Kotsopoulos, 2018; Kuchenbaecker et al., 2017a).  In addition to 
the increased personal risk, women with a BRCA pathogenic variant have a 50% chance of passing 
the pathogenic variant to their offspring (U. S. Preventive Services Task Force, 2019). 
Overall survival for BRCA associated breast and ovarian cancer is similar than that of 
women with breast or ovarian cancer who do not carry a BRCA pathogenic variant (Lieberman et 
al., 2019). However, due to the increased risk of cancer in these individuals, primary risk reduction 
strategies are often recommended, especially in those at increased risk for ovarian cancer.  Risk-
reducing surgical options may include bilateral mastectomy and bilateral salpingo-oopherectomy 
(U. S. Preventive Services Task Force, 2019).   For a young woman who is not ready to make 
family planning decisions, these surgical procedures can be significantly life altering (U. S. 
Preventive Services Task Force, 2019). 
Much research has focused on the myriad of issues associated with women who have tested 
positively for a BRCA pathogenic variant.  In the past ten years, requests for pathogenic variant 
testing have increased twofold to threefold (Evans et al., 2015; Juthe et al., 2015). Studies have 
identified factors influencing the decision to have BRCA testing including age, and the number of 




2016; Lynch et al., 2006; Nelson et al., 2005; Pasacreta, 2003).  Women with a BRCA pathogenic 
variant who have been diagnosed with cancer have experienced an increase in symptoms of 
distress, anxiety and depression in the first few months after genetic test disclosure (Beran et al., 
2008; Bosch et al., 2012; Claes et al., 2004; Graves et al., 2012; Halbert et al., 2011; Schwartz et 
al., 2002; Smith et al., 2008; van Dijk et al., 2006).  Other research has focused on the decision to 
have risk-reducing surgery. These studies also found this decision to be influenced by age, in 
addition to the desire for children, gender of living children and a family history of cancer 
(Battistuzzi et al., 2019; Gavaruzzi et al., 2017; Hesse-Biber, & An, 2016).   
Although women want to be logical in their decision-making, emotions may complicate 
this process.  By definition, emotions are complex, multi-dimensional judgments that reflect a 
great deal of information about one’s relationship to social and physical surroundings.  One’s own 
internal thoughts regarding these relationships are also reflected (Lambie & Marcel, 2002; Smith 
& Ellsworth, 1985).  Strong evidence supports the association of emotions and the decision to be 
tested for a BRCA pathogenic variant (Dean et al., 2017a; Rini et al., 2009; Werner-Lin, 2008).  
However, the role that emotions play in the reproductive decision-making process of women with 
a BRCA pathogenic variant is unknown.  Qualitative studies have examined the complex decisions 
influencing finding a partner and the timing of having children (Dean, 2016; Dean, & Rauscher, 
2017a; Dean et al., 2017b; Donnelly et al., 2013b; Rauscher et al., 2017).  However, no studies 
were identified that focused on the emotional aspect of reproductive decision-making. 
Lazarus and Folkman’s Transactional Model of Stress provides the foundation to better 
understand the effects of emotion on healthcare decision-making (Bagneux et al., 2012; Lerner et 
al., 2005; Lerner et al., 2001; Lerner et al., 2014; Lerner et al., 1999).  This model includes three 




These emotional states are accompanied by core appraisal themes, which influence the likelihood 
of specific courses of action (Frijda, 2002; Lazarus, 1991; LeBlond, 2008).  Threat is referred to 
as the anticipation of psychological or physical damage or loss; challenge results from demands 
that a person feels confident about mastering and loss/benefit refers to psychological loss or gain 
that has yet to occur.   
Women diagnosed with a BRCA pathogenic variant face difficult decisions about 
childbearing.  Previous research suggests that marriage and relationship status, as well as views 
about their use, acceptability and awareness of fertility options affect women’s childbearing 
decision-making.  Women with a known BRCA pathogenic variant have a sense of urgency in 
prioritizing childbearing over cancer risk management.  Some researchers have noted that single 
women who test positive for a BRCA pathogenic variant experience urgency to find a partner.  
These women desire someone who is emotionally and financially secure, understands their 
pathogenic variant status, and is supportive of their reproductive decision-making.   
Research has shown that women with children were more likely to undergo preventive 
surgery than childless women. They struggle with the idea that their children may inherit the 
pathogenic variant and often have feelings of sadness and guilt. These findings are consistent with 
previous research that has focused on opinions influencing the decision to be tested for 
a BRCA pathogenic variant.  
As more women learn their genetic breast or ovarian cancer risks, they must grapple with 
difficult decisions about reproductive life planning.  The emotional aspects of this decision-making 
are not well understood and requires additional study. Identifying the emotions and personal 
values influencing reproductive decision-making will help nurses provide psychological support 
and compassionate, knowledgeable care. 
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The purpose of this study is to explore the role of emotional states on reproductive decision-
making in women with a known BRCA pathogenic variant.   
4.2 Background 
The breast cancer genes, BRCA1 and BRCA2, are tumor suppressor genes that play a role 
in DNA repair and cellular growth control.  When either of these genes have a pathogenic variant, 
or are altered, DNA damage may not be repaired properly, and as a result, cells are more likely to 
develop genetic alterations that lead to cancer development.  Women with a germline pathogenic 
variant in the BRCA genes have an increased risk of early-onset breast and increased overall risk 
of ovarian cancers.  About 12% of the general population will develop breast cancer at some point 
in their lives. 72% of women who inherit a BRCA1 pathogenic variant and about 69% of women 
who inherit a BRCA2 pathogenic variant will develop breast cancer by the age of 80.  Similarly, 
about 1.3% of women in the general population will develop ovarian cancer sometime during their 
lives.  By contrast, it is estimated that about 44% of women who inherit a BRCA1 pathogenic 
variant and about 17% of women who inherit a BRCA2 pathogenic variant will develop ovarian 
cancer by the age of 80 (Kuchenbaecker et al., 2017b).   
In light of these high cancer risks, options available for managing cancer risk in these 
individuals include enhanced surveillance, chemoprevention and risk-reducing surgery.   
Enhanced surveillance consists of screening- some women who test positive for a BRCA1 
or BRCA2 pathogenic variant are recommended to start breast cancer screening at younger ages, 
than women at average risk of breast cancer.  Women with a BRCA pathogenic variant are 
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encouraged to begin breast self-awareness at the age of 18, schedule clinical breast exams every 6 
to 12 months beginning at age 25, and depending on the breast cancer history within the family, 
undergo annual breast MRI’s (magnetic resonance imaging) starting at the age of 25 (Committee 
on Practice Bulletins- Gynecology, 2017).  For BRCA mutation carriers, annual mammograms and 
MRI’s are recommended at the age of 30; for comparison, those not at an increased risk begin 
mammograms at the age of 40.  Additionally, breast self-awareness should begin at the age of 18.  
Chemoprevention is the use of medication in an attempt to reduce the risk of cancer.  In 
pre- and postmenopausal women, tamoxifen can be used for risk reduction which may reduce 
breast cancer risk.  Oral contraceptives have been found to reduce the risk of ovarian cancer due 
to the inhibitory effect on ovulation.  Oral contraceptives are known to reduce the risk of ovarian 
cancer, although they increase the risk for breast cancer.   
Risk reducing surgeries involve removing as much of the ‘at risk’ tissue as possible. 
Women can choose to undergo a bilateral prophylactic mastectomy (surgery that removes a 
woman’s breasts) to reduce their risk of breast cancer, and/or bilateral prophylactic salpingo-
oopherectomy, surgery that removes a woman’s ovaries and fallopian tubes.  Previous research 
results have shown that women with BRCA pathogenic variants who undergo risk-reducing 
mastectomies reduce their risk of developing breast cancer by 90% or more.  Similarly, undergoing 
a bilateral salpingo-oophorectomy reduces a woman’s risk of ovarian cancer by nearly 90%. 
To manage this increased risk, the American Society of Clinical Oncology, the National 
Comprehensive Cancer Network and the United States Preventive Services Task Force have put 
in place recommendations for women with this genetic mutation.  Risk-reducing surgery is 
recommended between the ages of 35-40 for BRCA1 pathogenic variant carriers and between the 




emphasized that risk-reducing surgeries remain the most complete way to reduce the risk of breast 
and ovarian cancer in women with a BRCA pathogenic variant.   
However, the challenge to adhering to risk-reducing guidelines for women with a BRCA 
pathogenic variant is that when surgery is discussed, some women may not have started their 
families, or they are unsure that they are finished.  This can lead to difficult decisions as the woman 
must balance her desire for family completion with their own risk-reduction measures.  
Since carrying a BRCA pathogenic variant is associated with an autosomal dominant 
inheritance pattern, the probability of transmitting a deleterious pathogenic variant is 50%.  For 
women who desire for their children to be biological, this is something they must consider, as they 
are made aware that any biological child has a 50% chance of carrying a BRCA mutation. 
Hence, women without children may be more distressed about completing their families 
before they may feel that their timeline is up.  Decision-making conflict surrounding the timing of 
risk-reducing surgery and childbearing has been commonly expressed by women who are young 
adults.  For those women who choose to undergo risk-reducing surgery before their family plans 
are complete, decisions may need to be made regarding whether they want their children to be 
biological and if so, free of the BRCA pathogenic variant.  Preimplantation genetic diagnosis 
(PGD), as part of the standard IVF process, allows for the selection and transfer of unaffected 
embryos that begins with standard IVF.  However, moral dilemmas may arise when choosing 
between embryos that do or do not carry the BRCA pathogenic variant.  Consideration may be 
given to using a donor egg or sperm.   
For women who may not be in relationships, cryopreservation techniques, such as the 
freezing of embryos and oocytes, the use of a gestational carrier, or adoption are other options that 




Making decisions under uncertain circumstances is especially relevant for women who are 
BRCA positive.  Much research has focused on decision-making in regard to the surgical decisions, 
as well as the decision to undergo genetic testing in women who have a known family history of 
breast or ovarian cancer.  Research has demonstrated that women with a BRCA pathogenic variant 
experience urgency to have children by the age of 35, hence making these decisions an emotionally 
charged experience. 
Various factors have been shown to influence patients’ decision making, especially 
pertaining to family formation, including age, risk-reducing surgery, and marital status.  
Reproductive decision making is highly individualized and difficult.  Previous research has 
demonstrated that female BRCA carriers seek assistance for reproductive decision making.  
Specifically, they identified themes concerning the psychosocial impact of carrying a BRCA 
pathogenic variant, including feelings of guilt about passing the pathogenic variant to current and 
future children.  Previous qualitative research, primarily from Dr. Rebekah Hamilton, highlighted 
challenges facing the younger population of women, including difficulties with decision making, 
and how to disclose pathogenic variant status to potential partners.  It is clear that emotions play 
an important role in the decision, but it is unclear which emotions are predominant.  
Acknowledging these motions can guide nurses to recognize patient concerns, discuss healthcare 
issues and provide the decision support needed for this vulnerable population.    
The Appraisal of Life Events scale was developed in response to the need to measure 
primary appraisals based on the Transactional Model of Stress.  In this model by Lazarus and 
Folkman, stressful experiences are presented as person to environment transactions, where the 
impact of an external stressor is mediated by the person’s response to the stressor.  According to 




strategies.  An appraisal is defined as a ‘cognitive predisposition to appraise future events that 
trigger the emotion’.  Patterns of cognitive appraisals along dimensions of emotion provide a basis 
for comparing and contrasting discrete emotions.  When individuals confront a stressful situation, 
primary and secondary appraisals are initiated.  In primary appraisal, a person considers the quality 
and the nature of the stimulus event and the relevance of that event to themselves.  When a stressor 
is appraised as requiring a coping response, individuals evaluate their resources and abilities to 
cope with the stressor.  This is known as a secondary appraisal. An appraisal driven approach 
allows one to systematically examine the effects of emotions on decision-making.  Basic 
dimensions are believed to underlie primary appraisals, such as threat, challenge and loss/benefit.   
The Appraisal of Life Events Scale was developed to allow respondents to reflect on the 
impact of a previously examined event.  Threat is referred to as the anticipation of psychological, 
or physical damage or loss; challenge results from demands that a person feels confident about 
mastering, and loss/benefit refers to psychological loss or gain that has yet to occur.  
Previous research has explored the relationship of appraisal and coping in women and men 
experiencing infertility concerns.  Evidence supported significant associations of the Appraisal of 
Life Events scale with stress measures, and with coping.  It was found that appraisal of infertility 
as threat or loss were associated with increased infertility-related stress, whereas viewing infertility 
as a challenge was related to increased well-being.  Another study used the Appraisal of Life 
Events Scale to assess appraisals in women experiencing infertility.     As more women learn their 
genetic breast or ovarian cancer risks, they must grapple with difficult decisions about reproductive 
life planning.  The emotional aspects of this decision-making are not well understood and requires 
additional study.  Identifying the emotions and personal values influencing reproductive decision-




The primary purpose of this study was to explore the role of emotional states on 
reproductive decision making in women with a known BRCA pathogenic variant.   
4.3 Methods 
4.3.1 Design and Sample 
With Institutional Review Board approval, secondary analysis was conducted using data 
from participants of the Cancer Family Registry.  This registry is a repository of data that can be 
used by researchers that is housed at the Cancer Genetics Program at UPMC Magee-Womens 
Hospital.  The women included in this database have previously consented to being contacted 
regarding their interest in participating in new research studies.  In this secondary analysis, an 
exploratory, descriptive study design was implemented, with additional variables collected 
through participant phone calls.  The convenience sample for this study included individuals who 
agreed to participate in future research studies.  Informed consent was obtained at the time of data 
collection.   
The inclusion criteria for this study included women who were between the ages of 18 - 
45, had a known BRCA pathogenic variant, confirmed by genetic testing, and were literate English 
speakers.  Originally, the inclusion criteria included all women over the age of 18; however, it 
might not be appropriate to include women who were over the age of 45, since they would likely 
not be making decisions about having children.  Thus, the age range was reduced to 18-45 years 






Demographic and Patient Characteristics 
A sociodemographic form, designed to gather participant information, collected current 
age, age at diagnosis, race, ethnicity, marital status, number of children and family history of breast 
and/or ovarian cancer.  These items were self-reported from the Cancer Family Registry and 
confirmed through use of this form.  Current age and age at diagnosis of BRCA mutation were 
measured as a single number, self-reported, in complete years, confirmed via the medical record.  
Race was measured as American Indian, Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, and White.  Ancestry was self-reported as both the paternal 
and maternal ancestry.  Marital status was measured as never married, married or living as married 
(with a partner), separated, divorced, or widowed.  Number of children was measured as a single 
number and family history of breast/ovarian cancer was measured as yes/no.  Reproduction 
decision-making was measured as a single response to the question ‘are you finished having 
children?’ with responses being either ‘yes’ or ‘no’.  BRCA pathogenic variant status was recorded 
from the Cancer Family Registry as either BRCA1 or BRCA2.  
Appraisal of Life Events Scale 
Emotional states will be measured by the Appraisal of Life Events scale. The items on the 
Appraisal of Life Events scale are measured according to dimension.  There are 32 response items, 
16 in each of two categories, asking to what extent an adjective describes or described an event.  
In the case of this scale, the event is making a family planning decision under a BRCA diagnosis.  
Each item is ranked on a scale from 0-5.  From those individual scores, the sum of certain 
individual items will correspond to one of the dimensions: threat, loss/benefit or challenge.  The 




Follow-Up Phone Call 
Based on the preliminary data results, a follow up phone call and questionnaire was 
appropriate to clarify the data that received.  This phone call asked participants whether or not 
BRCA affected their decision to have children, how many children they had after their diagnosis 
and whether they were biological or adopted, if they froze their eggs, if cost was a factor in their 
decision-making and other outside factors that may have influenced their decision.   
4.3.3 Data Analysis 
Analyses were performed using SPSS version 27 for Mac (IBM Corp, New York, USA) 
Descriptive Analyses 
Descriptive statistics were computed for each variable based on level of measurement, 
distribution of data and which statistic provided the most meaningful information.  Means and 
standard deviations, as well as ranges were used to describe continuous variables that were 
normally distributed.   For interval/ratio scaled variables that were not normally distributed, as 
well as ordinal/scaled variables demonstrating normal distributions, medians and inter-quartile 
ranges will be used.  Ranges were reported for nominal scaled variables.    For continuous variables 
with skewed distributions, medians were computed.  Frequencies and percentages were reported 
for categorical variables    
Data Screening 
Normality 
Assumptions for normality were assessed, looking at observation of test statistics, 
including skewness and kurtosis, as well as histogram and scatter plots.  There was no 
multicollinearity or heteroscedasticity observed among study variables.  Normality was assessed 
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using descriptive statistics, histograms, residual distributions, skewness and kurtosis.  Data 
transformation (e.g. square root transformation, categorizing data) was considered for any variable 
not meeting this underlying assumption. 
Univariate and Multivariate Outliers 
An outlier is a case of an extreme value on one variable, termed a univariate outlier, while 
multivariate outliers have unusual combinations of scores of two or more variables (Tabachnick, 
& Fidell, 2007).  Categorical variables were investigated by determining the frequency 
distributions over categories.  For continuous variables, histograms, boxplots, normal probability 
plots and de-trended normal probability plots will be used to identify points that are far removed 
from the bulk of the data.  In addition, Z-scores were computed to assess how extreme the 
identified univariate outliers were for continuous variables.  If a z-score was greater than the 
critical value of 3.29, or less than the critical value, the data point was considered an outlier. 
Because of the limited variability, the race and ancestry variables were used for descriptive 
purposes only rather than in multivariate analysis.  
A visual screening of histograms and box plots was used to identify univariate outliers, 
while multivariate outliers were evaluated statistically using Mahalanobis distance. Mahalanobis 
distance at p <.001 was used as the cut-off criteria (Tabachnick et al., 2007).  For categorical 
variables, outliers will be identified using frequency distributions to check for any uneven category 
splits.  All identified outliers were deemed to be valid members of the population and 
representative of the variability in the scales. 
Linearity and Homoscedasticity 
89 
Linear relationships among pairs of measured continuous variables were evaluated through 
visual inspection of bivariate scatter plots. Problems with heteroscedasticity would have been 
corrected using data transformations, but this was not necessary. 
Missing Data 
Analysis of incomplete data to determine patterns of missing data was completed. Less 
than 5% of subjects were missing data on all variables. Evaluation of the patterns of missing data 
indicated that the data were missing at random. Mean imputation was used to estimate missing 
values on all continuous variables. 
Multicollinearity 
Multicollinearity was assessed by screening 1) the correlation matrix for all of the 
variables, identifying correlations >.90; 2) tolerance values, with values <.3 indicating 
multicollinearity; and 3) variance inflation factor (VIF), with values >3 indicating possible 
multicollinearity.  None of the variables had correlations greater than .90 and all tolerance and VIF 
factors fell within the acceptable limits.  Interaction terms (used in logistic regression) typically 
demonstrate problems with multicollinearity. To avoid this problem, continuous variables entered 
as interaction terms in the logistic regression model were centered.  Multicollinearity was not 
found to be a problem with the measures in this study. 
Data Transformations 
Linearity in the logit describes a linear relationship between continuous predictors and the 
logit transformation of the dependent variable.  This was tested by running a logistic model with 
the DV (reproductive decision-making) predicted by each of the continuous variables plus the 
interactions between each predictor and its natural log.  We looked at whether the interaction term 




we found that there were no interactions that were significant, thus there was no violation of 
linearity in the logit. 
Specific Aim 1: Describe the distribution of a BRCA pathogenic variant among 
women who are in the Cancer Family Registry. 
Analysis: Appropriate descriptive statistics (e.g., mean, standard deviation, range) based 
on the empirical distribution of the data were used to characterize the sample of women in this 
study with a BRCA pathogenic variant with respect to reproductive decision-making, which was 
measured as ‘Are you finished having children’?   
The analysis involved calculation of descriptive statistics of the key study variables. All 
variables will be described using frequency distributions and summarized using appropriate 
measures of central tendency and dispersion given the variable’s level of measurement and 
observed data distribution (i.e., means and standard deviations for interval/ratio scaled variables 
demonstrating normal distributions; medians and inter-quartile ranges for ordinal scaled variables 
and interval/ratio scaled variables that are non-normally distributed; modes and ranges for nominal 
scaled variables).    
Specific Aim 2:  Explore the association between emotional states and reproductive 
decision-making.   
Analysis:  Binary logistic regression was used to investigate the association between 
individual emotional states and the probability of being finished having children (reproductive 
decision-making).  Emotional states measured mean scores on three dimensions of threat, 
challenge and loss/benefit.  Univariate binary logistic regression analyses were performed to 
estimate crude and adjusted odds ratios with 95% confidence intervals (CI).  For each of the 
emotional state variables, the test statistics, unadjusted odds ratios, adjusted odds ratios and 
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corresponding standard errors and p-values were reported.  The Hosmer-Lemeshow test was 
employed to evaluate the goodness of fit of the model.  Model fit was evaluated using classification 
tables and pseudo r-squared values (Cox & Snell and Nagelkerke).   
Specific Aim 3:  Explore the association between individual factors (age, marital 
status, number of children and family history of breast and ovarian cancer) and reproductive 
decision-making.   
Analysis:  Binary logistic regression was used to investigate the association between 
individual factors (age at genetic testing, marital status, number of children and family history of 
breast/ovarian cancer) and the probability of being finished having children (i.e., reproductive 
decision-making).  Certain variables, such as marital status, had relatively small number of cases 
in certain categories.  Therefore, ‘married’ and ‘living with partner’ were grouped together as 
‘partnered’ and ‘widowed’, ‘divorced’ and ‘never married’ were grouped together as ‘not 
partnered’.  Further, family history of breast cancer was split into individual categories based on 
relationship with the participant.  This included categories of ‘mother breast cancer’, ‘grandmother 
breast cancer’, aunt breast cancer’, ‘sister breast cancer’ and ‘cousin breast cancer’.   
Univariate analyses were initially performed considering each individual factor singly in 
the regression model.  Unadjusted and adjusted odds ratios with their corresponding 95% 
confidence intervals (CI) were reported. For each of the individual factor variables, the test 
statistics, unadjusted regression coefficients, adjusted regression coefficients and corresponding 
standard errors and p-values were reported.  The Hosmer-Lemeshow test was employed to evaluate 
to goodness of fit of the model.  Model fit was evaluated using classification tables and pseudo r-
squared values (Cox & Snell and Nagelkerke).    The level of significance was set at p< 0.05 for 




Aim 4:  Explore how BRCA pathogenic variant status (BRCA1 vs BRCA2) moderates 
the relationship between emotional states and reproductive decision-making.    
Analysis:  We constructed hierarchical multivariable binary logistic regression models for 
the primary outcome of interest, reproductive decision-making.  All possible two-way interactions 
were assessed, entering emotional states and BRCA pathogenic variant status hierarchically into 
the model.  Using this approach, emotional states were first entered into the model; BRCA 
pathogenic variant status was then added to the second block in this model.  Interaction effects 
were tested as part of the model building to determine whether there was any moderation by BRCA 
pathogenic variant status on emotional states and the probability of being finished having children.  
Main effects and 2-way interactions were estimated in the model.  Models were estimated 
hierarchically and subsequent model assessment strategies included residual, outlier and 
influential case analyses. Model fit was evaluated using change in chi-square statistics, 
classification tables, pseudo r-squared values (Cox & Snell and Nagelkerke), and the Hosmer and 
Lemeshow Test for adequate fit of the data. Significance levels were set a priori at .05, except 
where indicated. 
The moderator effect of BRCA pathogenic variant status on the relationship between 
emotional states and reproductive decision-making is indicated by the interaction of emotional 
states and BRCA pathogenic variant status in explaining reproductive decision-making.  A 
hierarchical regression analysis was conducted with emotional state, BRCA pathogenic variant, 
and the interaction of emotional state and pathogenic variant status (created as the product of the 
two variables) predicting reproductive decision-making. The coefficient of the interaction of two 
variables measures the moderation effect, with a no-significant coefficient indicating no 
93 
moderation effect.  Logistic regression was determined to be the type of regression because of the 
categorical manner of the dependent variable, reproductive decision-making.    
Aim 5:  Explore how individual factors moderate the relationship between emotional 
states and reproductive decision-making.   
Analysis:  A similar regression analysis strategy as outlined for Aim 4 will be used to 
explore the possible moderator effect of individual factors on the relationship between emotional 
states and reproductive decision-making.  The moderator effect of individual factors on the 
relationship between emotional states and reproductive decision-making is indicated by the 
interaction of emotional state and individual factors in explaining the probability of being finished 
having children.  A hierarchical regression will be conducted with each emotional state, individual 
factor and the interaction of emotional state and individual factors predicting reproductive 
decision-making.  To estimate moderation effects for individual factors on the relationship 
between the identified outcome variable and emotional states, the change in R2 statistic will be 
examined with the addition of the interaction term for individual factors with emotional states to 
the main effects model. 
We constructed hierarchical multivariable binary logistic regression models for the primary 
outcome of interest, reproductive decision-making.  All possible two-way interactions were 
assessed, entering emotional states and individual factors hierarchically into the model.  Using this 
approach, emotional states were first entered into the model; individual factors were then added to 
the second block in this model.  Interaction effects were tested as part of the model building to 
determine whether there was any moderation by the individual factors on emotional states and the 
probability of being finished having children.  Main effects and 2-way interactions were estimated 




included residual, outlier and influential case analyses. Model fit was evaluated using change in 
chi-square statistics, classification tables, pseudo r-squared values (Cox & Snell and Nagelkerke), 
and the Hosmer and Lemeshow Test for adequate fit of the data. Significance levels were set a 
priori at .05, except where indicated. 
4.4 Results 
4.4.1 Description of Sample Characteristics 
Of the 374 women who were sent mailings for this study, 85 (23%) responded to the 
mailing inquiries and provided demographic information and information relating to their 
emotions.  This study utilized single mailings, however, it is recognized that repeat mailings in an 
effort to increase response rate would have been preferred.   
Demographic data are summarized in Table 6.  The women in this sample ranged from 18-
45 years of age at diagnosis of BRCA pathogenic variant.  48 (56.5%) of the sample carried the 
BRCA1 pathogenic variant while 37 (43.5%) of the sample carried the BRCA2 pathogenic variant.  
This BRCA distribution was similar to the distribution of the Cancer Family Registry, from which 
this sample was obtained.  The majority of the sample (98%) was White, and the ancestry varied.  
For the most part, the ancestral background of the sample was from Europe.  More than half of the 
sample identified themselves as being Eastern European, both maternally and paternally (61% and 
54%, respectively) and most of the sample also reported having ancestry from the British Isles 
maternally and paternally (69% and 84%, respectively). 
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For the most part, women were married or partnered (70.6%).  Most women in the sample 
had children (81.2%), with a little more than half having one to two children (54.1%). 
Most of the sample was finished having children (82.3%).  The majority of the sample 
(96.5%) had a female relative diagnosed with either breast or ovarian cancer.  Specifically, most 
of the sample (52.9%) had a mother that was diagnosed with breast cancer, followed closely by 
grandmother and aunt.  Not unlike breast cancer, the number of women with a female relative with 




Table 6 Descriptive Variables of Women with a BRCA Pathogenic Variant 
Characteristic Are you finished having 
children? 




Mean + SD  
or n (%) 
 
No 
Mean + SD or 
n (%) 
BRCA1 
Mean + SD  
or n (%) 
 
BRCA2 
Mean + SD  
or n (%) 
 
 
Mean + SD  
or n (%) 
 
Age (years) 36.04 + 6.10 
(21-45) 
26.13 + 5.93 
(18-42) 
33.31 + 6.9 
(18-45) 
35.57 + 7.3 
(20-45) 
34.29 + 7.13 
(18-45) 
BReast CAncer gene (BRCA) 
          BRCA1 















          White 












































Number of Children 
          No children 
          1-2 children 





















Has your mother, 
grandmother(s), sister(s), aunt(s) 
or cousin(s) ever been diagnosed 
with breast cancer? 
Yes 
No 



































































Has your mother, 
grandmother(s), sister(s), aunt(s) 
or cousin(s) ever been diagnosed 






































































4.4.2 Association Between Emotional States and Reproductive Decision-Making 
When looking at the association between emotional states and reproductive decision-
making, (Aim 2), the results showed that none of the emotional states were significantly associated 
(p ≥ .05) for reproductive decision-making, individually or collectively.   
Table 7 Binary Logistic Regression of the Probability of Being Finished Having Children Considering Emotional 
States Individually (Crude/Unadjusted) and Collectively (Adjusted)  
Emotional 
State 
Crude (Unadjusted) p-value Adjusted p-
value 











1.016 0.950 1.086 .648 0.985 0.899 1.079 .751 
Challenge 
Score 
1.052 0.925 1.197 .441 1.047 0.922 1.189 .478 
Loss/Benefit 
Score 
1.056 0.937 1.191 .372 1.071 0.911 1.259 .407 
4.4.3 Association Between Individual Factors and Reproductive Decision-Making 
 When examining the relationship between individual factors and reproductive decision-
making, there was significant prediction of reproductive decision-making by age at genetic testing 
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(p=.001) and number of children (p=.001).  Surprisingly, marital status and family history of breast 
or ovarian cancer were not significant predictors.  
Based on the follow up questionnaire, 74% of the sample did not have children after 
learning about their diagnosis.  26% did have children, and of those individuals, 98% had 
biological children.  3 individuals used PGD to assist with their reproduction and only 1 individual 
froze their eggs.   
Table 8 Binary Logistic Regression Results of Probability of being Finished Having Children Considering 










95% CI for OR Odds 
Ratio 









Age at Genetic 
Test (years) 
1.290 1.135 1.466 .001 1.322 1.125 1.553 .001 
Marital Statusa 2.528 0.803 7.962 .113 0.710 0.098 5.149 .735 
Number of 
Childrenb 
2.917 1.567 5.432 .001 2.784 1.157 6.702 .022 
Aunt with 
Breast Cancer 




1.281 0.419 3.918 .664 1.038 0.191 5.650 .965 
Sister with 
Breast Cancer 
1.773 0.360 8.731 .482 0.797 0.047 13.475 .875 
Mother with 
Breast Cancer 
1.357 0.444 4.151 .592 4.739 0.697 32.214 .112 
Cousin with 
Breast Cancer 





0.696 0.227 2.129 .525 1.982 0.315 12.471 .466 
Notes. 
aThe combined category of married/living with a partner was treated as the reference group for 
marital status compared to widowed/divorced/never married. 
bThe grouped category of >1 child was treated as the reference group for number of children 
compared to no children.     
4.4.4 Moderation of BRCA Pathogenic Variant Status on Relationship between Emotional 
States and Reproductive Decision Making 
To the models developed to address Aim 2, BRCA was added as a moderator between 
emotional states and reproductive decision making.  In the first step, two variables were included: 
emotional states and reproductive decision-making.  Next the interaction term between emotional 
states and BRCA pathogenic variant status was added to the regression model.  None of these 
interactions were statistically significant.  In looking at the variables in the first step of the model, 
there were no significant interactions between BRCA variant status and emotional states.  When 
we expanded the model to include the interactions between emotional states and BRCA variant 
status, we found no significant interactions, considering each emotional state individually, as well 
as collectively.  The Hosmer-Lemeshow test was not significant, suggesting that the data fit the 
model adequately (X2 = 7.998, df = 7, p= .333). The model correctly classified 92.9% of 
participants: 34.6% of those finished having children and 95.7% of those not finished having 
children.   
From the follow-up questionnaire, we found that 75% of the sample said that their BRCA 
diagnosis did not affect their decision to have children.  The most significant reasons were that 
they were done having children (they already had the number of children they desired) or they 
wanted children regardless and were not letting a BRCA diagnosis define their choice to have 
children.  One average, the participants who were older in the study felt that BRCA did not affect 
their decision.    
Of the 25% that reported that a BRCA diagnosis did affect their decision to have children, 
it all came down to timeline.  Most of these women felt rushed to complete their childbearing, 
knowing that they had a limited window.   
Table 9 Multivariate Logistic Regression Results with All Predictors Included 
Predictor Adjusted p-value
Odds Ratio 95% CI 
Lower Limit Upper Limit 
Threat 0.978 0.865 1.106 0.727 
Challenge 1.140 0.913 1.424 0.246 
Loss/Benefit 1.057 0.863 1.296 0.590 
BRCA2a 1.049 0.806 1.366 0.721 
Threat × BRCA statusa 1.009 0.824 1.234 0.934 
Challenge × BRCA 
statusa 
0.865 0.662 1.131 0.291 
Loss/Benefit × BRCA 
statusa 
1.052 0.734 1.507 0.784 
Notes. 
aBRCA1 pathogenic variant is the reference group 
4.4.5 Moderation of Individual Factors on Relationship between Emotional States and 
Reproductive Decision-Making 
The only model that suggested moderation was between loss/benefit and any family history 
of ovarian cancer (X2(1) = 5.760, p= .016).  Women who reported higher loss/benefit scores and 
had a female relative with ovarian cancer were more likely to be finished having children.  The 
Hosmer-Lemeshow test was not significant, suggesting that the data fit the model adequately 
(X2 = 3.234, df = 7, p= .863). The model correctly classified 82.4% of participants: 33.3% of 
those finished having children and 92.9% of those not finished having children. 
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Lower Limit Upper Limit 
Threat × Age 1.008 0.992 1.024 .345 
Threat × Marital Statusa 1.025 0.891 1.179 .729 
Threat × Number of Children 0.974 0.906 1.046 .467 
Threat × Aunt with Breast 
Cancerb
0.928 0.807 1.068 .296 
Threat × Grandmother with 
Breast Cancerb 
0.998 0.873 1.141 .978 
Threat × Sister with Breast 
Cancerb 
1.087 0.896 1.319 .398 
Threat × Mother with Breast 
Cancerb 
1.041 0.909 1.192 .560 
Threat × Cousin with Breast 
Cancerb 
1.208 0.718 2.034 .477 
Threat × Female Relative with 
Ovarian Cancerb
0.907 0.787 1.045 .177 
Challenge × Age 1.009 0.974 1.045 .621 
Challenge × Marital Statusa 0.768 0.563 1.048 .096 
Challenge × Number of 
Children  
1.090 0.930 1.277 .287 
Challenge × Aunt with Breast 
Cancerb 
0.909 0.690 1.199 .500 
Challenge × Grandmother with 
Breast Cancerb 
1.022 0.788 1.328 .867 
Challenge × Sister with Breast 
Cancerb 
1.000 0.698 1.432 .998 
Challenge × Mother with Breast 
Cancerb 
0.900 0.687 1.179 .445 
Challenge × Cousin with Breast 
Cancerb 
0.516 0.088 3.020 .463 
Challenge × Female Relative 
with Ovarian Cancerb 
0.965 0.741 1.257 .792 
Loss/Benefit × Age 1.023 0.986 1.061 .222 
Loss/Benefit × Marital Statusa 0.872 0.655 1.161 .347 
Loss/Benefit × Number of 
Children  
1.027 0.890 1.185 .718 
Loss/Benefit × Aunt with Breast 
Cancerb 
0.883 0.686 1.137 .336 
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Loss/Benefit × Grandmother 
with Breast Cancerb 
1.004 0.787 1.281 .974 
Loss/Benefit × Sister with 
Breast Cancerb 
1.283 0.884 1.863 .190 
Loss/Benefit × Mother with 
Breast Cancerb 
1.309 0.943 1.817 .108 
Loss/Benefit × Cousin with 
Breast Cancerb 
1.519 0.807 2.863 .195 
Loss/Benefit × Female Relative 
with Ovarian Cancerb 
0.595 0.390 0.909 .016 
Notes. 
aThe combined category of married/living with a partner was treated as the reference group for 
marital status 
bRelative with breast cancer was treated as the reference group for family history of cancer 
Figure 6 Predicted Probability of Being Finished Having Children for Female Relative with Ovarian Cancer and 
Loss Beneft Score 
Another theme that we found among respondents was around financial constraints.  94.4% 
of the sample did not feel that financial constraints prevented them from making the reproductive 
decision that they did.   
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Women noted that the factors that most influenced their decision to have children came 
down to their self or spouse’s desire to have children, and their quality of life. 
4.5 Discussion 
To our knowledge, this study was the first to assess the impact of emotional states on 
reproductive decision-making, while assessing for moderation of a BRCA pathogenic variant, and 
individual factors of age at genetic testing, marital status, number of children and family history 
of breast and ovarian cancer.  In our study of 85 women with a BRCA pathogenic variant, we 
assessed emotions thought to be specific to women making reproductive decisions.  Consistent 
with previous research, BRCA-related decisions are wrought with emotions.  Specifically, this 
study identified that women who were older, already had children and had a family history of 
ovarian cancer were more likely to report being finished having children.       
Family history of ovarian cancer was the only familial related variable significant in any 
of the models.  This was not surprising because with the BRCA pathogenic variant, family 
implications are particularly strong, especially when considering the gene’s autosomal dominant 
inheritance and high cancer penetrance.  Most research explores family risk in the context of testing 
choices, when another family member is diagnosed with breast or ovarian cancer.  Women in 
families with a strong cancer history are usually aware that they could follow the family pattern 
and develop cancer as well (Dean, & Rauscher, 2017a; Graves et al., 2012; Hamilton et al., 2009; 
Kenen et al., 2003; Kenen et al., 2007; Raveis et al., 2005) and they tend to perceive their personal 
risk as higher if their mother or sister had cancer (Douglas et al., 2009; Kenen et al., 2004; Raveis, 
& Pretter, 2005).  As a result, women tend to undergo surgery earlier to decrease their chances of 
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receiving a cancer diagnosis.  In addition, with a family history of ovarian cancer, the resulting 
surgery is the removal of ovaries, which renders a woman infertile.  A family history of breast 
cancer may be considered less severe, since with a mastectomy, one may still be able to bear 
children.        
The emotional scale items from the Appraisal of Life Events Scale were not significant in 
any model.  These results indicate that either these emotions are not predominant in reproductive 
decision-making, or perhaps a more descriptive question needed to be asked to assess the impact 
of emotional state.  Previous research has shown that it is an emotional experience that presents 
challenges for women making reproductive-related decisions, particularly those who are younger 
(Hamilton, 2012).  Younger age is associated with both higher perceptions of stigma and cancer-
specific anxiety and has also been associated with an increased sense of urgency in both life-
partnering and childbearing (Hamilton, & Hurley, 2010; Werner-Lin, 2008).  However, further 
research needs to be done to interpret the impact of timing since test disclosure on decision-making 
and the role of the emotions in this relationship.      
The BRCA pathogenic variant status was not a significant moderator.  This means that 
whether having BRCA1 vs BRCA2 was not a significant moderator in the relationship between 
emotional states and reproductive decision-making.  The BRCA1 pathogenic variant is associated 
with increased risks of cancer, more so than BRCA2.  Thus, it was hypothesized that BRCA1 would 
have a significant moderating effect.  BRCA1 carries a higher likelihood of cancer than BRCA2, 
thus individuals with this pathogenic variant are generally recommended surgery earlier than those 
with BRCA2.  Previous literature has not identified differences in uptake of surgery, or 
reproductive decisions among women with BRCA1 vs BRCA2 pathogenic variants, and this study 
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was no different.  Further research is needed to assess the specific differences, if present, among 
BRCA1 vs BRCA2 pathogenic variant carriers.       
Age at genetic testing and number of children were significant in the model predicting 
reproductive decision-making.  This was not particularly surprising.  Consistent research has 
shown that women who have children prior to BRCA test disclosure feel less conflict with making 
further reproductive choices.  Additionally, women who are older in age are more likely to be 
partnered, and have children, thus making their reproductive decision plans more concrete.  This 
seemed to be consistent with the findings from this study and further confirmed with use of the 
follow-up phone call.  The women who were older tended to express that their BRCA diagnosis 
had no effect on their reproductive decision-making.  Prior research has shown that younger 
women tend to be more distressed after genetic testing for the BRCA mutation than older women 
(Lodder et al., 2002; Watson et al., 2004).  Anxiety and depression also have been found to be 
associated with age at the time of genetic testing (Bennett et al., 2008).  In our study, age at genetic 
testing was significant when predicting reproductive decision making, but was not significant 
when assessing emotions.        
4.5.1 Limitations of the Study 
The study primarily was based upon secondary data analysis; however, several new 
variables were added.  Retrospective research suffers from the risk of missing data, mistakes 
during the interpretation of data or incorrect documentation.  The time difference from genetic 
testing and reproductive decision-making could have been an extraneous factor not considered 
during analysis.  Based on the follow-up survey, 74% of the study sample was done having children 
by the time they were tested for BRCA, so the findings on decision making are effectively only for 
26% of the population.  Future studies should correct for this timeline.  In addition, some variables 
were only able to be used as descriptive variables, rather than analytic variables.  Future studies 
should try to include these variables in a manner that they can analyzed, as they may be important 
to the larger scope of the results.     
Despite adequate power to conduct analyses, the response rate to study mailings was lower 
than expected.  A larger sample is preferred to demonstrate more power in detecting significance 
among statistical tests.  Some relationships that were predicted to have significance did not show 
this, and the small sample size could have played a role in this.  Researchers have suggested to 
have a preferred sample size over 400 for logistic regression (Bewick, Cheek, & Ball, 2005; 
Hosmer & Lemeshow, 2000).  Overall, study participants did not differ extremely from 
nonparticipants identified by the Cancer Family Registry as potentially eligible.  On 
average, responders were about one year younger than non-respondents and marital status was 
similar.  Even though the response rate was low, there did not appear to be drastic differences 
between those who responded and those who did not.  Had there been differences, strategies to 
reduce bias would be undertaken in future studies.  Additionally, this study only utilized a 
single mailing to obtain results.  The use of repeated mailings and/or the use of reminder 
postcards would be an effective way to increase the sample size for future studies.        
Finally, all instruments used in the study were self-reported measures.  While some of the 
information could be checked with medical records, there is still a chance that the data could not 
have been completely accurate.  Although the use of self-report is often used in research studies, 
this may introduce recall bias and social desirability.   
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4.6 Future Studies and Implications 
Study design and recruitment are important considerations for the advancement of familial 
cancer science.  Future research should move to longitudinal studies to 1) understand how emotion 
changes over time and 2) identify vulnerable phases in the reproductive decision-making 
trajectory.  To maximize cancer prevention and risk reduction, as well as give women the most 
options they can have, it is critical to understand decision-making from a woman’s standpoint. 
Previous research on the impact of counseling on psychosocial impacts of those counseled noted 
the importance of encouraging individuals to talk more during patient clinical counseling.  This 
might, in turn, lead to improved outcomes in clinical risk communication, such as decreased 
distress and greater knowledge gains.  Considering a range of psychosocial and relational factors 
in women’s nexus of decision-making may facilitate and provide a range of rich pre and post-
testing treatment options that empower women’s medical decision-making abilities and improve 
their overall health and psychosocial outcomes.   
Although the results of this study did not show us what we expected it to, there is still much 
more than can and should be done with regard to assessing emotional states and reproductive 
decision-making in women with a BRCA pathogenic variant.  One potential future direction for 
this study includes prospective, longitudinal studies to assess young women receiving BRCA 
testing. A prospective longitudinal study would allow us to study decision regret, which could be 
an important component of this research.  Not only would we be able to get the concurrent 
experience, but could also observe how that experience plays out over time.  Do people becomes 
more convinced that they made the right decision and are they comfortable with that decision?  Or 
as time goes on, do they begin to regret that decision?  Current research presented by Dr. Andrew 
Dwyer at ISONG 2020, emphasized that perceived behavioral control (autonomy) is important for 
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increasing satisfaction and minimizing regret, especially among those with familial genetic 
disorders..  By identifying how risk perceptions change, especially as they near an age when they 
believe that their risks might increase, as well as following their management options over time, it 
will allow for a full-circle view and exactly what these individuals go through with their family 
planning and allow for exploration of that decisional regret component.  Additionally, collecting 
data at the time of decision-making would likely give a more reliable view of emotions and 
decision making as the memory of emotions may fade over time.     
  Also, men may experience distress due to guilt associated with a cancer of BRCA 
diagnosis in their daughters and would be an avenue to explore.  Additionally, there are specific 
ancestral backgrounds that research has suggested BRCA mutations have comparable prevalence 
in.  By utilizing a study where women undergo ancestry testing to get the specific ancestry 
background, this might allow for a more precise look at ancestries that are associated with higher 
incidences of the BRCA pathogenic variant.   
There are social and ethical implications associated with reproductive decision-making- 
such as the use of fertility assistance through PGD or cryopreservation.  Identifying the prevalence 
of use, as well as the emotions that are associated with the use of these methods would be an area 
ripe for exploration.  Finally, there are women of lower socioeconomic status that are 
underrepresented in terms of receipt of genetic services.  Interventions to increase access to genetic 
testing and counseling in these women would allow for more well-rounded and holistic care.   
With increased demands being placed on people’s time and attention, survey response rates 
have been declining and costs have been rising.  Attention should be paid to addressing reasons 
for non-participation in this study (increased age, privacy/providing information).  Future research 
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should also focus on conducting studies that are sensitive to the challenges and perspective of more 
diverse groups of BRCA affected individuals.    
Immediate next studies should include efforts to only include the study sample that 
responded that BRCA affected their decision to have children.  By only including these women in 
the study, it would give a better view as to the significance of emotions on reproductive decision-
making.  In addition, employing efforts to increase the sample size to validate results would be a 
way to further confirm the findings from this study.    
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5.0 Summary of Study 
Women who live in the United States have a 12% risk of developing breast cancer and a 
2% risk of developing ovarian cancer during their lifetime.  For women who carry a pathogenic 
BRCA1 or BRCA2 variant, one that affects approximately one in 200-400 women living in the 
United States, this risk increases (Kuchenbaecker et al., 2017a; Manickam et al., 2018).  For breast 
cancer, lifetime risk ranges from 55-70% for BRCA1 carriers by the age of 70 and between 45-
70% in BRCA2 carriers.  For lifetime risk of ovarian cancer, the risk ranges from 40-45% for 
BRCA1 and 15-20% for BRCA2 (Kotsopoulos, 2018; Kuchenbaecker et al., 2017a).  In addition to 
the increased personal risk, women with a BRCA pathogenic variant have a 50% chance of passing 
the pathogenic variant to their offspring (U. S. Preventive Services Task Force, 2019). 
Due to the increased risk of cancer in these individuals, primary risk reduction strategies 
are often recommended, especially in those at increased risk for ovarian cancer.  Risk-reducing 
surgical options may include bilateral mastectomy and bilateral salpingo-oopherectomy (U. S. 
Preventive Services Task Force, 2019).   For a young woman who is not ready to make family 
planning decisions, these surgical procedures can be significantly life altering, especially in 
bilateral salpingo-oophorectomy, which renders a woman infertile (U. S. Preventive Services Task 
Force, 2019). 
Much research has focused on the myriad of issues associated with women who have tested 
positively for a BRCA pathogenic variant.  Although women want to be logical in their decision-
making, emotions may complicate this process.  By definition, emotions are complex, multi-
dimensional judgments that reflect a great deal of information about one’s relationship to social 
and physical surroundings.  Strong evidence supports the association of emotions and the decision 
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to be tested for a BRCA pathogenic variant (Dean et al., 2017a; Rini et al., 2009; Werner-Lin, 
2008).  However, the role that emotions play in the reproductive decision-making process of 
women with a BRCA pathogenic variant is unknown.  Lazarus and Folkman’s Transactional Model 
of Stress provides the foundation to better understand the effects of emotion on healthcare 
decision-making (Bagneux et al., 2012; Lerner et al., 2005; Lerner et al., 2001; Lerner et al., 2014; 
Lerner et al., 1999).  This model includes three basic dimensions, or emotional states; threat, 
challenge, and loss/benefit (Folkman et al., 1985).  These emotional states are accompanied by 
core appraisal themes, which influence the likelihood of specific courses of action (Frijda, 2002; 
Lazarus, 1991; LeBlond, 2008).  This study strived to determine if the emotional states of threat, 
challenge and loss/benefit, as outlined by the Transactional Model of Stress and measured using 
the Appraisal of Life Events (ALE) Scale, played a role on the reproductive decision making in 
women with a BRCA pathogenic variant.   
A review of the literature found that women diagnosed with a BRCA pathogenic variant 
face difficult decisions about childbearing.  The results of this review suggest that marriage and 
relationship status, as well as views about their use, acceptability and awareness of fertility options 
affect women’s childbearing decision-making.  Women with a known BRCA pathogenic variant 
have a sense of urgency in prioritizing childbearing over cancer risk management.  Some 
researchers have noted that single women who test positive for a BRCA pathogenic variant 
experience urgency to find a partner.  These women desire someone who is emotionally and 
financially secure, understands their pathogenic variant status, and is supportive of their 
reproductive decision-making.   
This review of the literature further found that women with children were more likely to 
undergo preventive surgery than childless women. Women with a BRCA pathogenic variant 
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struggle with the idea that their children may inherit the pathogenic variant and often have feelings 
of sadness and guilt. These findings are consistent with previous research that has focused on 
opinions influencing the decision to be tested for a BRCA pathogenic variant.  As more women 
learn their genetic breast or ovarian cancer risks, they must grapple with difficult decisions about 
reproductive life planning.  The emotional aspects underlying reproductive decision-making are 
not well understood and requires additional study. Identifying the emotions and personal 
values influencing reproductive decision-making will help nurses provide psychological support 
and compassionate, knowledgeable care. 
This study utilized an exploratory, descriptive methodology designed to describe the 
association between emotion and reproductive decision-making in women who tested positive for 
the BRCA pathogenic variant.  Participants were sought from the Cancer Family Registry, and 
were mailed a packet containing a consent form, an ALE scale, demographic/family history 
questionnaire and a prepaid return envelope.  The sociodemographic form was designed to gather 
participant information and collected current age, age at diagnosis, race, ethnicity, marital status, 
number of children and family history of breast and/or ovarian cancer.  These items were self-
reported from the Cancer Family Registry and confirmed during data collection.  Reproduction 
decision-making was measured as a single response to the question ‘are you finished having 
children?’ with responses being either ‘yes’ or ‘no’.  BRCA pathogenic variant status was recorded 
from the Cancer Family Registry as either BRCA1 or BRCA2.  Emotional states were measured by 
the Appraisal of Life Events scale, measured according to dimension.  There were 32 response 
items, 16 in each of two categories, asking to what extent an adjective described a family planning 
decision under a BRCA diagnosis.  Each item was ranked on a scale from 0-5.  From those 
individual scores, the sum of certain individual items corresponded to one of the dimensions: 
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threat, loss/benefit or challenge.  The higher the score, the higher the appraisal of threat, challenge 
or loss/benefit respectively.  Based on the preliminary data results, a follow up phone call and 
questionnaire was appropriate to clarify the data that received.  This phone call asked participants 
whether or not BRCA affected their decision to have children, how many children they had after 
their diagnosis and whether they were biological or adopted, if they froze their eggs, if cost was a 
factor in their decision-making and other outside factors that may have influenced their decision. 
The sample was split relatively evenly between those with a BRCA1 vs a BRCA2 
pathogenic variant and this was representative of the Cancer Family Registry.  On average, women 
with a BRCA2 pathogenic variant were about 2 years older at diagnosis than those with a BRCA1 
pathogenic variant.  98% of the sample was White, and more than half of the sample identified 
themselves as being Eastern European.  Most of the sample was married or partnered and a little 
more than half reported having 1-2 children.  The majority of the sample had a female relative 
diagnosed with either breast or ovarian cancer.  Specifically, most of the sample (52.9%) had a 
mother that was diagnosed with breast cancer, followed closely by grandmother and aunt.  Not 
unlike breast cancer, the number of women with a female relative with ovarian cancer was high 
(45.9%).  Again, those numbers were highest among mothers, grandmothers and aunts.  Logistic 
regression results showed that none of the emotional states were significant for predicting 
probability of being finished having children.  The individual variables that were significant for 
reproductive decision-making were age at genetic testing and number of children.  Based on the 
follow-up questionnaire, 74% of the study participants did not have children after learning about 
their diagnosis.  26% did have children, and of those individuals, 98% had biological children.  3 
individuals used PGD to assist with their reproduction and only one individual froze their eggs.   
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When the moderating effect of BRCA pathogenic variant status on emotional states and 
reproductive decision-making was analyzed, there were no significant interactions, considering 
each emotional state individually, as well as collectively.  Further, based on the follow-up 
questionnaire, we found that 75% of the sample said that their BRCA diagnosis did not affect their 
decision to have children.  The most significant reasons were that they were done having children 
(they already had the number of children they desired) or they wanted children regardless and were 
not letting a BRCA diagnosis define their choice to have children.  On average, older participants 
felt that knowing they carried a BRCA pathogenic variant did not affect their decision.  Of the 25% 
that reported that a BRCA diagnosis did affect their decision to have children, it was due to personal 
timelines.  These women felt rushed to complete their childbearing, knowing that they had a 
limited window.  
Finally, when looking at the moderating effect of the individual factors on emotional states 
and reproductive decision-making, we found one significant interaction between family history of 
ovarian cancer and loss/benefit scores, indicating that women who reported higher loss/benefit 
scores and had a female relative with ovarian cancer were more likely to be finished having 
children.   
This study was the first to assess the impact of emotional states on reproductive decision-
making, while assessing for moderation of a BRCA pathogenic variant and individual factors.  The 
emotional scale items from the Appraisal of Life Events Scale were not significant.  However, 
further research is needed to interpret the impact of timing since test disclosure on decision-making 
and the role of the emotions in this relationship.  The results of this study are limited by the fact 
that 74% of the study participants had completed their families by the time they were tested for 
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BRCA.  This means that the results from this study are valid for only 26% of the study population. 
Future studies should correct for this timeline. 
  The BRCA pathogenic variant status was not a significant moderator.  The results of this 
study are consistent with the literature that has not identified differences in the number of 
prophylactic surgical procedures, or reproductive decisions made among women with BRCA1 vs 
BRCA2 pathogenic variants. Further research is needed to assess the specific differences, if 
present, among BRCA1 vs BRCA2 pathogenic variant carriers.   
Analysis of study participants compared to the nonparticipants identified by the Cancer 
Family Registry as potentially eligible did not differ. On average, responders were about 1 year 
younger than non-respondents (BRCA1: 32.45 years and BRCA2: 34.94 years) and marital status 
was similar (BRCA1: 69.3% partnered, 30.7% unpartnered and BRCA2: 71.7% partnered and 
28.3% unpartnered).  Had there been differences, strategies to reduce bias would be undertaken in 
future studies.  This study sample included only women who were under the age of 45; there were 
374 women who met the initial inclusion criteria.  After accounting for those women who were 45 
years and younger, 85 women out of the returned 123 surveys were eligible for inclusion in the 
study.   
Future studies should include a prospective, longitudinal design to assess young women 
receiving BRCA testing.  Using a prospective design would allow decisional regret to be explored, 
which could be an important component of this research.  Not only would we be able to study the 
concurrent experience, but could also observe how that experience plays out over time.  Are 
women convinced that they made the right decision and are they comfortable with that decision? 
Or as time goes on, do they begin to regret that decision?  By identifying how risk perceptions 
change, especially as women near an age when they believe that their risks might increase, as well 
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as following management options over time, it will allow for a full-circle view at exactly what 
these individuals go through with their family planning.  This will also allow for exploration of a 
decisional regret component.   By collecting data at the time of decision-making, this would likely 
give a more reliable view of emotions and decision making as the memory of emotions may fade 
over time.   
In conclusion, emotions may play a role in the reproductive decision-making of women 
with a positive BRCA pathogenic variant.  Age at genetic testing and number of children, as well 
as a family history of ovarian cancer play a significant role in relation to loss/benefit and 
reproduction decision-making.  These findings may, over time, help to guide interventions to 
empower women’s medical decision-making abilities and improve their overall health and 
psychosocial outcomes.       
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Human Research Protection Office




   Institutional Review Board
www.hrpo.pitt.edu
Pitt_510_EXP
APPROVAL OF SUBMISSION (Expedited) 
Date: October 15, 2019
IRB: STUDY19050345
PI: Elizabeth Skrovanek




The Institutional Review Board reviewed and approved the above referenced study.  The study may 
begin as outlined in the University of Pittsburgh approved application and documents. 
Approval Documentation





• Demographic Information, Category: Data Collection;
• Appraisal of Life Events Scale, Category: Data Collection;
• Consent form, Category: Consent Form;
• Introductory letter, Category: Recruitment Materials
As the Principal Investigator, you are responsible for the conduct of the research and to ensure accurate 
documentation, protocol compliance, reporting of possibly study-related adverse events and 
unanticipated problems involving risk to participants or others. The HRPO Reportable Events policy, 
Chapter 17, is available at http://www.hrpo.pitt.edu/.
Clinical research being conducted in an UPMC facility cannot begin until fiscal approval is received from 
the UPMC Office of Sponsored Programs and Research Support (OSPARS). 
If you have any questions, please contact the University of Pittsburgh IRB Coordinator, Dana DiVirgilio.
Please take a moment to complete our Satisfaction Survey as we appreciate your feedback.
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Thank you so much for your continued support in the Cancer Family Registry!  My 
name is Elizabeth Skrovanek and I am a doctoral student at the University of 
Pittsburgh School of Nursing.  I am conducting this research study as part of my 
dissertation work to better understand and support women who have a BRCA 
mutation and are making decisions about their family planning.    
  
You will receive a $20 gift card for completing the questionnaire and survey.    
  
There will be no benefit to your participation in this study.  Your participation is 
completely voluntary and you may withdraw at any time.  
  
A breach of confidentiality is possible as your name will be collected with your 
information.  However, all measures will be taken to ensure that your privacy will be 
protected.  Your name and personal information will not be associated with any study 
data and will be kept in a separate location.     
  
First, please review and complete one copy of the Consent form included with this 
mailing.  The signed consent form must be returned along with your questionnaire 
and survey responses in order for us to include you in the study.  You will receive a 
copy of this consent form when you receive your $20 gift card as thanks for 
completing the documents.   
  
As a study participant you will be asked to:  
  
x Complete the included paper survey and questionnaire and return it along with 
the signed consent form in the included prepaid envelope.    
x The survey will ask about emotions that you may have experienced while you 
were thinking about your family planning.  This survey should take you less 
than 30 minutes to complete.  If you need a break, you can come back to the 
survey later.  
x The questionnaire will ask for information about your background and family 
history.  
x Your participation in this research study might help us increase our 
understanding of the support needed by young women with a BRCA mutation 
as they make family planning decisions.    
  
After we receive your signed consent form, survey and questionnaire, we will mail you 
a gift card and a copy of your signed consent form.     
  
Please note that your responses to this questionnaire will not be sent to your 
healthcare providers.  It is important that you contact or see your professional  
  
   
healthcare team if you have any questions or concerns about any emotional 
symptoms or your genetic testing results.    
  




Elizabeth Skrovanek BSN, PhD (s)     Phuong L. Mai, MD, MS  
University of Pittsburgh School of Nursing   UPMC Cancer Genetics Program  
415 Victoria Building         Magee-Womens Hospital of UPMC  
3500 Victoria Street        300 Halket Street, Suite 1651  
Pittsburgh, PA  15213        Pittsburgh, PA 15213    
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 VOLUNTARY CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
 
TITLE:  Emotions Associated with Reproductive Decision Making in Women with a BRCA Gene 
Mutation 
 
PRINCIPAL INVESTIGATOR: Elizabeth Skrovanek BSN, PhD(s) 
      Doctoral Student 
      Health Promotion and Development 
      440 Victoria Building 
      University of Pittsburgh 




SOURCE OF SUPPORT: Judith Erlen Scholarship Fund; University of Pittsburgh School of Nursing  
 
About 1 in 200 women living in the United States has a BRCA mutation.  You are being asked to 
participate in a research study to determine the impact of emotions on your reproductive decision 
making (how you have made or are making decisions around completing your family). We are inviting 
you to participate because you are a woman above the age of 18 and have been identified to have a 
BRCA gene mutation.   
 
 
The goal of this study is to determine the impact of certain emotions on reproductive decision 
making in women with a BRCA gene mutation.  We are aiming to recruit 75 participants for 
this study.     
 
During the study, this is what will happen:   
 
1). Complete the enclosed survey.  It will ask you to check off some words that describe the 
emotions that you might have felt or are feeling while making a decision about your reproductive 
planning.  This survey should take approximately 30 minutes to complete.   
 
2). Complete a demographics form.  This form will ask you to fill out some information about you, 
such as your age, your marital status, ancestry, number of children that you have and if you have any 
family history of breast or ovarian cancer.   
Susan Wesmiller 
PhD, RN  
Professor 
Health Promotion and 
Development 













     412-641-7449 
 
     Susan Sereika PhD 
Professor 
Health and 
Community Systems  
School of Nursing 
University of 
Pittsburgh 
     412-624-0799 
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If you have any questions regarding the study, consent, survey or anything about the study, please do 
not hesitate to call the PI.      
 
The following risk could be associated with participation in this research study: 
 
There is a risk of breach of confidentiality: that is, in very rare cases, people not associated with this 
research study may inadvertently see the identifiable research results.    
 
To protect your privacy and maintain confidentiality of information we obtain from you, we will 
keep all information about your study information in a secure location.  All paper records that could 
identify you will be stored in locked file cabinets kept in a locked office.  All electronic records will be 
stored in password protected files.  Your identity on these records will be indicated by a case number 
rather than by your name, and the code linking your name to this number will be maintained 
separately with very limited access to research team members.  
Your participation in this research study is entirely voluntary.  
Whether or not you provide your consent for participation in this research study will have no effect on 
your current or future relationship with the University of Pittsburgh. Whether or not you provide your 
consent for participation in this research study will have no effect on your current or future medical 
care at a UPMC hospital or affiliated health care provider or your current or future relationship with a 
health care insurance provider. 
• Before agreeing to participate in this research study, or at any time during your study 
participation, you may discuss your care with another doctor who is not associated with this 
research study. You are not under any obligation to participate in any research study offered 
by your doctor. 
You will be paid $20.00 to take part in this study.  
 
Your participation in this research study is completely voluntary.  Whether or not you participate 
will have no effect on your current or future relationship with the University of Pittsburgh, Magee 
Women’s Hospital or its affiliated health care providers or health insurance providers.  If you decide 
you no longer wish to participate after you have signed the consent form, you should contact the PI, 
Ms. Elizabeth Skrovanek at 724-719-8068.   
You can, at any time withdraw from this research study; you can also withdraw your authorization for 
us to use your identifiable medical information for the purposes described above. This means that you 
will also be withdrawn from further participation in this research study. Any identifiable research or 
medical information obtained as part of this study prior to the date that you withdrew your consent will 
continue to be used and disclosed by the investigators for the purposes described above. 
• To formally withdraw from this research study, you should provide a written and dated notice of 
this decision to the principal investigator of this research study at the address listed on the first 
page of this form. Your decision to withdraw from this study will have no effect on your current 
or future relationship with the University of Pittsburgh. 
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• Your decision to withdraw your consent for participation in this research study will have no 
effect on your current or future medical care at a UPMC hospital or affiliated health care 





All of the above has been explained to me and all of my current questions have been answered.  I 
understand that I am encouraged to ask questions about any aspect of this research study during the 
course of this study, and that, such questions or any concerns should be addressed by Ms. 
Skrovanek.  At any point, I may also contact the Human Subject Protection Advocate of the IRB 
Office, University of Pittsburgh (1-866-212-2668) to discuss problems, concerns and questions, to 
obtain information; offer input; or discuss situations in the event that the research team is unavailable.  
 
By signing this form, I agree to participate in this research study and authorize the use and disclosure 
of my medical record information for the purposes described above.   A copy of this consent form will 




____________________________________   ____________________________ 




CERTIFICATION of INFORMED CONSENT 
 
I certify that I have explained the nature and purpose of this research study to the above-named 
individual(s), and I have discussed the potential benefits and possible risks of study participation.  
Any questions the individual(s) have about this study have been answered, and we will always be 
available to address future questions as they arise. I further certify that no research component of this 
protocol was begun until after this consent form was signed.  
 
 
___________________________________  ________________________ 




_________________________________  _________________________ 








Appendix D Demographic Questionnaire 
Demographic Questionnaire 
 
Please fill out the following questions.  Please answer the questions to the best of your 
ability.   
 
 
Current Age:  _________________ 
 
 
Age when you had your genetic test: _________________________ 
 
 
Identified Race- please circle one: 
 
Native Hawaiian or Other Pacific Islander          White 
 
 
Ethnicity- please circle one: 
 




Ancestry- please list the ancestry for your father’s and mother’s side of 
the family on the respective lines: 
 
 
Ancestry (father) ____________________ 
 
 





Married   Widowed   Divorced or Separated  
 
 
Never Married  Living with a Partner  
 
 





American Indian or Alaska Native            Asian    
      
 
Black or African American  
 
 
Are you Finished Having Children? 
 




Has your mother, sister(s), aunt(s) or grandmother(s) ever been 
diagnosed with breast cancer? 
 
Yes    No 
 
 




Has your mother, sister(s), aunt(s) or grandmother(s) ever been 
diagnosed with ovarian cancer? 
  
   Yes    No 
 
 


































The following survey will ask you some questions about your family 
planning and how you felt while making your family plans.  Please 
answer the questions to the best of your ability; there are no right or 
wrong answers. You may use the back of the paper if you need more 
space to write.   
ALE-Scale (Retrospective recall version) 
In the space provided, please describe your decision making around your family planning 
and if your BRCA diagnosis affected this planning.  This can include how you decided to 
















We would like you to rate your perceptions of the above event you have just described. Use 
the following six point scales (where 0 = not at all to 5 = very much so) to indicate the extent to 
which each of the adjectives best describes your perceptions of the event when it occurred. Do 
this by circling the appropriate point on the scales. 
Please respond as quickly as possible as first responses are usually more 
accurate. Please make a response to each adjective. 
AT THE TIME IT OCCURRED THE EVENT WAS: 
 
(1) Threatening: 































































































































ALE Scale - (Situational version) 
 
We would like you to rate your perceptions of your current circumstances. That is your perception 
of your thoughts and feelings right now. Use the following six point scales (where 0 = not at all to 
5 = very much so) to indicate the extent to which each of the adjectives best describes your 
perceptions now. Do this by circling the appropriate point on the scales. Please respond as quickly 
as possible as first responses are usually more accurate. Please make a response to each adjective. 
I FIND MY CURRENT CIRCUMSTANCES: 
 
(1) Threatening: 

























































































































































COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)


























COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
























COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)


































COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
































COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)


























COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)
























COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)





























COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)



























COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)


































COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI PROGRAM)





























































My name is Elizabeth Skrovanek, from the University of Pittsburgh School of Nursing.  You 
recently completed a survey for my study of women at risk for breast and ovarian cancer.   Thank 
you so much.   
I had 2-3 follow-up questions that I was hoping you would be willing to answer if you have time?  
 (If she says she does not have time now):   If not, is there a better time for you?   
 (If she says she doesn’t have time to complete surveys): I can also send you an 
email message containing a link to answer the questions. Can you please provide 
me with an email address?   
 If she is not willing to complete over the phone or through email- thank you for 
your responses to my survey.  I appreciate your time. 
 
You indicated that:                            BRCA did not affect your decision about having children 
                                                           BRCA did affect your decision about having children 
How many children did you have after learning about your diagnosis?  
 For those children, what was the specific decision that you made?  For example, 
were they biological (biological in this case means using your egg and your 
partner’s sperm)?  Adopted?   
 How did you decide to make that choice?   
 If biological, did you use a surrogate? 






I would like to ask about any financial constraints that might have influenced your decision, if you 
feel comfortable.  
 No, not comfortable 
 Yes, comfortable  
 Were there any financial constraints involved in your decision about having 
children?   
 If you did not make the choice that you wanted to, did you feel that financial 
constraints prevented you from making that choice? 
 How much would you say that cost factored into your decision about having 
children?  
 Not at all  
 A little bit  
 Somewhat  
 Quite a bit  
 Very Much 
Finally, were there any outside factors, or individuals, that influenced your decision?  These can 
include things like:                       
 Age at marriage 
 Quality of life 
 Social support 
 Self/spousal desire to have children 




Thank you so much for your response to these questions.  I appreciate the time that you spent to 
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